ARTICLE TITLE: American Cancer Society Colorectal Cancer Survivorship Care Guidelines

ONLINE CONTINUING EDUCATION ACTIVITY
Take free quizzes online at acsjournals.com/ce

CONTINUING MEDICAL EDUCATION ACCREDITATION AND DESIGNATION STATEMENT:
Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Blackwell Futura Media Services designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION ACCREDITATION AND DESIGNATION STATEMENT:
The American Cancer Society (ACS) is accredited as a provider of continuing nursing education (CNE) by the American Nurses Credentialing Center’s Commission on Accreditation.
Accredited status does not imply endorsement by the ACS or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity. The ACS gratefully acknowledges the sponsorship provided by Wiley for hosting these CNE activities.

EDUCATIONAL OBJECTIVES:
After reading the article “American Cancer Society Colorectal Cancer Survivorship Care Guidelines,” the learner should be able to:
1. Describe potential long-term and late effects of colorectal cancer and its treatment.
2. Discuss ACS recommendations for follow-up care of colorectal cancer survivors by primary care clinicians.

ACTIVITY DISCLOSURES:
This journal article was supported, in part, by Cooperative Agreement #5U55DP003054 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. No industry funding was used to support this work.

ACS CONTINUING PROFESSIONAL EDUCATION COMMITTEE DISCLOSURES:
Editor, Director of Continuing Professional Education, and ACS Director of Medical Content:
Ted Gansler, MD, MBA, MPH, has no financial relationships or interests to disclose.
Deputy Editor and ACS Director of Cancer Control Intervention:
Durado D. Brooks, MD, MPH, has no financial relationships or interests to disclose.
Lead Nurse Planner and Associate Editor:
Marcia Grant, RN, PhD, FAAN, has no financial relationships or interests to disclose.
Associate Editor and Chief Cancer Control Officer:
Richard C. Wender, MD, has no financial relationships or interests to disclose.

NURSING ADVISORY BOARD DISCLOSURES:
Maureen Berg, RN, has no financial relationships or interests to disclose. Susan Jackson, RN, MPH, has no financial relationships or interests to disclose. Barbara Lesser, BSN, MSN, has no financial relationships or interests to disclose.

AUTHOR DISCLOSURES:
Nicole L. Erb, BA, reports cooperative agreement funding from the American Cancer Society/Centers for Disease Control and Prevention (ACS/CDC) for the National Cancer Survivorship Resource Center project. Anne Willis, MA, reports cooperative agreement funding from the ACS/CDC for the National Cancer Survivorship Resource Center project as well as a grant from Genentech and event sponsorships from Amgen Oncology, Takeda Oncology, and Genentech outside the submitted work. Jennifer K. Bretsch, MS, reports cooperative agreement funding from the ACS/CDC for the National Cancer Survivorship Research Center project. Mandi L. Pratt-Chapman, MA, reports cooperative agreement funding from the ACS/CDC for the National Cancer Survivorship Resource Center project as well as a grant from Genentech; a consulting fee from Pfizer; and event sponsorships from Amgen Oncology, Genentech, and Takeda Oncology outside the submitted work. Rachel S. Cannady, BS, reports cooperative agreement funding from the ACS/CDC for the National Cancer Survivorship Resource Center project. Mandi L. Pratt-Chapman, MA, reports cooperative agreement funding from the ACS/CDC for the National Cancer Survivorship Resource Center project as well as a grant from Genentech; a consulting fee from Pfizer; and event sponsorships from Amgen Oncology, Genentech, and Takeda Oncology outside the submitted work. Rebecca L. Cowens-Alvarado, MPH, reports cooperative agreement funding from the ACS/CDC for the National Cancer Survivorship Resource Center project. April L. Barbour, MD, MPH, FACP, Durado D. Brooks, MD, MPH, Khaled El-Shami, MD PhD, Kevin C. Oeffinger, MD, Katherine B. Sharpe, MTS CPH, and Kevin D. Stein, PhD, have no financial relationships or interests to disclose.

SCORING
A score of 70% or better is needed to pass a quiz containing 10 questions (7 correct answers) or 80% or better for 5 questions (4 correct answers).

CME INSTRUCTIONS ON RECEIVING CME CREDIT
This activity is intended for physicians. For information concerning the applicability and acceptance of CME credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 1.75 hours; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to 2 years from the time of initial publication.

CNE INSTRUCTIONS ON RECEIVING CNE CREDIT
This activity is intended for nurses. For information concerning the applicability and acceptance of CNE credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 1.75 hours; nurses should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to 2 years from the time of initial publication.

FOLLOW THESE STEPS TO EARN CREDIT
• Log on to acsjournals.com/ce.
• Read the target audience, educational objectives, and activity disclosures.
• Read the activity contents in print or online format.
• Reflect on the activity contents.
• Access the examination, and choose the best answer to each question.
• Complete the required evaluation component of the activity.
• Claim your certificate.
This activity will be available for CME/CNE credit for 1 year following its launch date. At that time, it will be reviewed and potentially updated and extended for an additional 12 months.
All CME/CNE quizzes are offered online FREE OF CHARGE. Please log in at acsjournals.com/ce. New users can register for a FREE account. Registration will allow you to track your past and ongoing activities. After successfully completing each quiz, you may instantly print a certificate, and your online record of completed courses will be updated automatically.
Colorectal cancer (CRC) is the third most common cancer and third leading cause of cancer death in both men and women and second leading cause of cancer death when men and women are combined in the United States (US). Almost two-thirds of CRC survivors are living 5 years after diagnosis. Considering the recent decline in both incidence and mortality, the prevalence of CRC survivors is likely to increase dramatically over the coming decades with the increase in rates of CRC screening, further advances in early detection and treatment and the aging and growth of the US population. Survivors are at risk for a CRC recurrence, a new primary CRC, other cancers, as well as both short-term and long-term adverse effects of the CRC and the modalities used to treat it. CRC survivors may also have psychological, reproductive, genetic, social, and employment concerns after treatment. Communication and coordination of care between the treating oncologist and the primary care clinician is critical to effectively and efficiently manage the long-term care of CRC survivors. The guidelines in this article are intended to assist primary care clinicians in delivering risk-based health care for CRC survivors who have completed active therapy.

**Keywords:** colorectal cancer, survivorship, clinical care, follow-up, guidelines, primary care, quality of life, survivorship care plan, long-term effects, late effects, care coordination

**American Cancer Society Colorectal Cancer Survivorship Care Guidelines**

Khaled El-Shami, MD, PhD1; Kevin C. Oeffinger, MD2; Nicole L. Erb, BA3*; Jennifer K. Bretsch, MS, CPHO3; Mandi L. Pratt-Chapman, MA4; Rachel S. Cannady, BS5; Sandra L. Wong, MD, MS6; Johnie Rose, MD, PhD7; April L. Barbour, MD, MPH, FACP10; Kevin D. Stein, PhD11; Katherine B. Sharpe, MTS12; Durado D. Brooks, MD, MPH13; Rebecca L. Cowens-Alvarado, MPH14.

To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go to acsjournals.com/ce.

Additional supporting information may be found in the online version of this article. Given the wide range of authors from varied disciplines, it is not intended to assist primary care clinicians in delivering risk-based health care for CRC survivors who have completed active therapy.

**DISCLOSURES:** This journal article was supported in part by Cooperative Agreement #5U55DP003054 from the Centers for Disease Control and Prevention Services/ACS (CDC) for the National Cancer Survivorship Resource Center project. The remaining authors have no financial disclosures to declare.

**Corresponding author:** Nicole L. Erb, BA, Program Manager, National Cancer Survivorship Resource Center, American Cancer Society, 250 Williams Street, NW, Suite 600, Atlanta, GA 30303; nicole.erb@cancer.org
Introduction

Over the past 2 decades, increasing attention has been given to understanding the long-term and late effects experienced by cancer survivors as a result of their cancer diagnosis or treatment.1-4 Long-term (side) effects caused by cancer or its treatment that are present during treatment and may persist for months or years may be physical or psychosocial in nature. In contrast, late effects of the cancer or cancer therapy may occur months or even years after a cancer diagnosis and again may include second cancers, physical problems, or psychosocial issues. Along the cancer continuum, there are at least 3 distinct phases of cancer survivorship: from diagnosis to the end of initial treatment, the transition from treatment to extended survival, and long-term survival.5 While clinical practice guidelines exist for diagnosis and treatment, there are few evidence-based clinical care guidelines for posttreatment care. The ever increasing number of cancer survivors living after treatment poses a challenge to oncology and primary care clinicians to provide ongoing optimal clinical follow-up care.6 To meet this demand, it is important to equip primary care clinicians with the necessary resources to recognize and manage the health risks and maximize quality of life (QoL) of cancer survivors. The National Comprehensive Cancer Network® (NCCN®) has developed consensus-based guidelines for the treatment of patients with colon and rectal cancers, which also include some recommendations regarding follow-up care after completion of treatment.7,8 In addition, the NCCN has developed survivorship care guidelines addressing long-term or late occurring psychosocial and physical problems and preventive health.9 In addition, the American Society of Clinical Oncology (ASCO) clinical practice guidelines for cancer survivorship care focus on prevention and management of symptoms experienced by survivors of many types of cancer. To date, ASCO has released 3 evidence-based cancer survivor care guidelines focused on fatigue, anxiety and depression, and neuropathy.10-12 ASCO has also updated their fertility preservation guideline13 and offers a provisional clinical opinion on the integration of palliative care into oncology care.14

The American Cancer Society (ACS) CRC Survivorship Care Guidelines build on previous guidelines by providing primary care clinicians with recommendations for providing comprehensive care for CRC survivors. These guidelines provide guidance on: 1) methods to identify and manage the potential physical and psychosocial long-term and late effects of CRC and its treatment, 2) surveillance for recurrence and screening for second primary cancers, 3) health promotion, and 4) how to enhance communication between the oncology team and primary care clinicians. The goal of these guidelines is to optimize care delivered for cancer survivors and to help improve the overall health and QoL of CRC survivors.

Gaps in posttreatment cancer survivorship resources and clinical follow-up care were identified through the work of the National Cancer Survivorship Resource Center, a collaboration between the American Cancer Society and The George Washington University Cancer Institute, funded by a 5-year cooperative agreement from the Centers for Disease Control and Prevention. (The Survivorship Center; cancer.org/survivorshipcenter).15 Aims of The Survivorship Center are to help survivors achieve optimal health and QoL and to increase awareness of posttreatment survivorship as a public health issue. To this end, The Survivorship Center convened a group of experts to review existing literature and clinical practices to develop comprehensive clinical follow-up care guidelines for CRC survivors, specifically those who are stage I-III, with no evidence of disease.

Background

Approximately 132,700 individuals will be diagnosed with CRC in the US in 2015.16 The incidence of CRC has declined over the past 20 years, in large part because of increased screening and removal of precancerous polyps. The rate of decline in incidence is greater among non-Hispanic white males than among African American males and is similar between non-Hispanic white and African American females.16 Other racial and ethnic groups have lower incidence rates than these 2 populations.17 Approximately 49,700 patients will die from CRC in 2015.16 Mortality rates are highest among African American males and are approximately 50% higher than rates in the second highest group, non-Hispanic white males, followed by American Indian/Alaska Native males. Among females, mortality rates are significantly higher for African Americans, followed by American Indians/Alaska Natives, and non-Hispanic whites17 (Fig. 1: Colorectal Cancer Incidence and Mortality Rates* by Race/Ethnicity and Sex, United States, 2006-2010).18

As of January 1, 2014, it is estimated that CRC survivors comprise more than 1.2 million (about 9%) of the nearly 15 million cancer survivors alive in the US, making CRC the second and third most common cancer site among male and female cancer survivors, respectively.19 The majority of CRC survivors are aged 60 years or older.16 The overall health and QoL experienced by survivors is influenced in part by the stage at diagnosis and the types and duration of therapy. Only 40% of CRC is diagnosed at a local stage (stages I and II), whereas 36% of cancers are diagnosed at a regional stage, involving the regional lymph nodes (stage III), and 20% are diagnosed at a distant stage, when distant metastases have occurred (stage IV).17 The type of treatment will vary, depending on the stage at diagnosis, but the most common treatment is surgery, with additional therapy including systemic chemotherapy and radiation therapy (the latter is used much more often in rectal cancer than in colon cancer) given either in the neoadjuvant or
adjuvant setting. Potential physical long-term and late effects affecting CRC survivors include chronic peripheral neuropathy, infertility, secondary cancers, and bowel dysfunction. Survivors may also experience psychosocial issues, such as distress, depression, anxiety, body image, sexual dysfunction and intimacy concerns, as well as financial issues resulting from workforce displacement and/or costs of treatment.20

Methods

Literature Review

To develop the ACS CRC Survivorship Care Guidelines, The Survivorship Center staff conducted an initial review of relevant literature and reviewed publically available US and international clinical practice guidelines. The original literature search was conducted in the fall of 2011 using PubMed, identifying articles published between 2000 and 2011 using combinations of the following keywords and phrases: cancer survivor, colon cancer, rectal cancer, colorectal cancer, chemotherapy, cognitive dysfunction, depression, distress management, fecal incontinence, follow-up care, genetic counseling and testing, guidance, guidelines, hand and foot syndrome, health promotion, late effects, late sequelae, long-term effects, meta-analysis, monitoring, neuropathy, pain management, palliative care, posttreatment, primary care physician, psychosocial, radiation, recurrence, screening, second cancer, sexual dysfunction, surgery, surveillance, survivor, survivorship, symptom management, systematic review, and treatment complications. Studies were excluded that 1) reported on studies of childhood cancer, 2) reported on qualitative studies, 3) were published in languages other than English, and 4) specifically addressed metastatic (stage IV) CRC (due to the likelihood that these survivors participate in ongoing treatment and do not fall into the “long-term/extended survivorship” phases).

In January and February 2012, the initial literature search was supplemented by an environmental scan of publically available US and international clinical practice guidelines and reports relevant to the clinical management of CRC patients and survivors, regardless of intended readership. Surveillance guidelines specific to CRC from the NCCN and national and international sources relevant to the impact of CRC and interventions for long-term and late effects were reviewed. Sources included the: ACS, American College of Gastroenterology, American Gastroenterological Association, American Psychosocial Oncology Society, ASCO, American Society of Colon and Rectal Surgeons, American Society for Gastrointestinal Endoscopy, American Society for Radiation Oncology, Canadian Association of Psychosocial Oncology, Institute of Medicine (IOM), National Cancer Institute, NCCN, National Guidelines Clearinghouse, MD Anderson Clinical Tools and Resources Colon and Rectal Cancer Survivorship algorithm, Oncology Nursing Society, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Gastroenterology Nurses and Associates, Inc., and Society of Surgical Oncology.

From May 2012 through June 2014, the CRC guideline was put on hold as The Survivorship Center directed its
efforts to writing the ACS Prostate Cancer Survivorship Care Guidelines manuscript. Prostate cancer is the first cancer type to be published in a series of new ACS survivorship care guidelines developed and funded in part through The Survivorship Center cooperative agreement.21 In September 2014, The Survivorship Center reconvened the ACS CRC Survivorship Care Guidelines Expert Workgroup to update the literature review, review the levels of evidence according to previously published methods, and consider any revisions. A small writing group was convened to complete the guidelines manuscript.

Due to the time lapse, in September 2014, an updated literature search was conducted. Search terms included cancer survivor + review or meta-analysis or systematic review + guidelines or guidance paired with colorectal cancer; colorectal cancer survivor or colorectal cancer patient post-treatment + (symptom management, late effects, long-term effects, psychosocial care, palliative care, health promotion, surveillance, screening for new cancers, self-management, guidelines or guidance, follow up or follow-up, side effects + chemotherapy, side effects + radiation, side effects + surgery, treatment complications, genetic counseling and testing, survivor or patient interventions, provider interventions, provider education, and barriers). Literature identified included: guidelines/guidance developed by other organizations (eg, NCCN follow-up recommendations, ASCO follow-up recommendations), specific medical centers (eg, The University of Texas MD Anderson Cancer Center), or other countries (eg, the Australian Cancer Survivorship Centre); recent meta-analyses and review articles (since 2004 after publication of the National Action Plan for Cancer Survivorship); and individual studies. The highest priority was given to articles that met the following criteria: peer-reviewed publication in English since 2004, unless a seminal article published before that date still carried the most weight, including randomized controlled trials (RCTs), prospective studies, and well-conducted, population-based, case-control studies; large studies of more than 200 cancer cases analyzed; and with high-quality assessment of covariates and analytic methods; and analyses controlled for important confounders (eg, pre-existing comorbid conditions).

In total, 226 articles (Literature Review Summary Table; see online supporting information) met the inclusion criteria for the literature review and were used to develop the guidelines.

**Literature Synthesis and Workgroup Recommendations**

In May 2012, The Survivorship Center staff integrated evidence from the initial literature review to develop an initial draft of the ACS CRC Survivorship Care Guidelines that was reviewed by the expert workgroup. The Survivorship Center Steering Committee and staff and the ACS medical and cancer control leadership nominated experts who were caring for CRC survivors in either primary care or surgical/oncologic settings. Workgroup members were selected based on their expertise in at least one of the following domains: gastroenterology, health services, medical oncology, oncology nursing, preventive medicine, primary care, public health, and surgical oncology. The expert workgroup consisted of 9 initial members who were e-mailed a structured 13-question survey about the accuracy and relevance of the draft guidelines document (Appendix A; see online supporting information). Written responses were compiled and distributed in advance of a conference call to discuss the feedback and reach consensus on conflicting recommendations.

Led by Khaled El-Shami, MD, PhD, of The GW Medical Faculty Associates, a Hematologist/Oncologist with board certification in Medical Oncology and Internal Medicine, the expert workgroup participated in a webinar discussion of the existing evidence base as well as themes and discrepancies from the comments. Based on written and verbal feedback, The Survivorship Center staff revised the draft guidelines. The Survivorship Center staff sought additional evidence and clinical expertise to support practice-based recommendations and to explore issues identified by the expert workgroup members that were not identified by the literature review. Based on a combination of published evidence and practice-based experience, The Survivorship Center staff drafted clinical follow-up care recommendations to be considered for inclusion in the guidelines. This revised draft of guidelines recommendations was presented to the American Cancer Society Mission Outcomes Committee, Chief Medical Officer, and National Board of Directors for review and was approved in May 2012.

In September 2014, the initial literature review was updated using the search terms outlined in the literature review section.21 Expert workgroup members were asked to consider the following criteria as they synthesized their findings from the published literature:

1. Level of evidence (defined as level I, meta-analyses of RCTs; level IA, RCT of CRC survivors; level IB, RCT based on cancer survivors across multiple sites; level IC, RCT based not on cancer survivors but on the general population experiencing a specific long-term or late effect [eg, managing urinary incontinence, erectile dysfunction, etc]; level IIA, non–RCT based on CRC survivors; level IIB, non–RCT based on cancer survivors across multiple sites; level IIC, non–RCT based not on cancer survivors but on the general population experiencing a specific long-term or late effect; level III, case study; and level 0, expert opinion, observation, clinical practice, literature review, or pilot study);
2. Consistency across studies, including across study designs (separating results by study design when presenting the evidence);
3. Dose-response when presenting long-term or late effects associated with chemotherapy or radiation therapy;
4. Race/ethnicity differences in diagnosis and treatment that may impact the risk of long-term or late effects; and
5. Second primary cancers for which CRC survivors are at high risk due to cancer treatment exposure, genetic factors, lifestyle behaviors, etc.

Although new articles were added to the literature review, there was no change in the guidelines. In May 2015, the guidelines manuscript was sent to internal and external experts for final review and comment before submission for publication. The process of cancer survivorship care guidelines development was aligned with the ACS process for creating cancer screening guidelines, and a comparison of this methodology has been previously published. In December 2011, changes were effected to ensure the ACS cancer screening guidelines development process was in alignment with the new IOM standards for how guidelines should be developed. To align with the ACS cancer screening guidelines process, every 5 years these survivorship care guidelines will be updated as new research is available to support revision.

**Guidelines for the Primary Care Management of CRC Survivors**

Each of the essential components of comprehensive cancer survivorship care are discussed in the following sections: Surveillance for CRC Recurrence and Screening for Second Primary Cancers, Assessment and Management of Physical and Psychosocial Effects of CRC and Treatment, Routine Health Promotion Needs, and Coordination of Care Among Specialists and Primary Care Clinicians.

**Surveillance for CRC Recurrence**

Surveillance for CRC recurrence is applicable to survivors who have completed primary treatment for stage I, II, and III cancer and are without evidence of disease (Table 1: Surveillance Guidelines for Colorectal Cancer Recurrence and Screening and Early Detection of Second Primary Cancers [Stage I-III]). The goal of surveillance is to detect recurrent or metachronous (eg, new primary) disease early, thereby improving long-term outcomes through timely intervention.

Although these guidelines can be extrapolated to surveillance strategies for patients with resected, metastatic (stage IV) CRC without evidence of disease, there are little to no data to inform these recommendations.

The ASCO clinical practice guideline endorsement of the Cancer Care Ontario Guidelines on Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer emphasized that if a patient is not a candidate for surgery or systemic therapy because of severe comorbid conditions, then surveillance tests should not be performed. Testing should only be performed in patients for whom the results will change treatment decisions. We endorse this ASCO recommendation.

**Recommendation 1: Clinical follow-up care provided to CRC survivors should be individualized based on the specific diagnosis and treatment protocol. Level of evidence = 2A**

The guiding principle of surveillance is that it should be based on assessment of a patient’s risk of recurrence in the context of functional status and patient preferences. Factors associated with a high risk of recurrence include poorly differentiated histology (exclusive of cancers with microsatellite instability-high [MSI-H]); lymphatic or vascular invasion; bowel obstruction; having had fewer than 12 lymph nodes examined; perineural invasion; localized perforation; and close, indeterminate, or positive resection margins.

In addition, unless there is a family history or a known genetic syndrome, CRC survivors are at average risk for other cancers, and it is recommended that primary care clinicians screen for second primary cancers as they would in the general population.

**Recommendation 2: CRC survivors should receive surveillance colonoscopy according to a schedule based on risk. Level of evidence = 2A**

The survivorship timeline (time zero) starts at the time of resection or at the time of diagnosis if resection is not part of index treatment (see Table 1). Testing intervals are based on the assumption that treatment is not ongoing and that no evidence of recurrence or metastatic disease was found at the end of treatment. The literature is not definitive with regard to how often surveillance for recurrent disease should be conducted and, to a lesser extent, which modalities to use for surveillance. In the US, there are surveillance guidelines from the NCCN and ASCO. These recommendations differ slightly because of differences in results from included clinical trials used to form guideline recommendations. Results from trials do not give a consistent answer to questions about an optimal surveillance program and, importantly, do not provide definitive evidence on outcomes related to early detection of recurrent disease or second primary tumors.

For survivors of colon and rectal cancers, the NCCN recommends the following surveillance schedule, which we endorse (see Table 1). For survivors of all stages of CRC, colonoscopy is recommended 1 year after resection unless no preoperative colonoscopy occurred due to emergent presentation, in which case, colonoscopy is recommended 3 to 6 months after surgery. If no abnormalities or advanced adenomas are found, then repeat colonoscopy is recommended at 3 years and every 5 years thereafter.
Generally, ASCO agrees with the NCCN recommendations but does not recommend the colonoscopy at 3 years. Rather, ASCO recommends colonoscopy every 5 years after the initial post-therapy colonoscopy. Detection of adenomatous polyps during surveillance will necessitate more frequent follow-up.

**Recommendation 3: CRC survivors should receive a history and physical every 3 to 6 months in the first 2 years, and every 6 months in years 3 through 5. Level of evidence = 2A**

For survivors of stage II and III cancers, for the first 2 years, physicians should take the patient’s history and conduct a physical examination as an opportunity to identify symptoms, offer counseling, and coordinate post-treatment care.

**Recommendation 4: Carcinoembryonic antigen testing should be conducted every 3 to 6 months for the first 2 years if a patient is a potential candidate for further intervention and every 6 months for years 3 through 5 if a patient is a potential candidate for further intervention; carcinoembryonic antigen testing is not recommended after 5 years. Level of evidence = 2A**

For the first 2 years, carcinoembryonic antigen (CEA) testing is recommended every 3 to 6 months. Over the next 3-5 years posttreatment

| GUIDELINE: LEVEL OF EVIDENCE AND CONSENSUS – 2Ab |
|-----------------------------------------------|
| 1-2 Years posttreatmentb                       |
| • H & P every 3-6 mo                          |
| • CEA every 3-6 mo if patient is a potential candidate for further intervention |
| • Chest/abdominal/pelvic CT every 12 mo (stages I-II if at high risk for recurrence and stage III) |
| • Colonoscopy in year 1; if advanced adenoma, repeat in 1 year; if not, repeat in 3 years |
| 3-5 Years posttreatmentb                      |
| • H & P every 6 mo                            |
| • CEA every 6 mo if patient is a potential candidate for further intervention |
| • Chest/abdominal/pelvic CT every 12 mo (stages I-II if at high risk for recurrence and stage III) |
| • Colonoscopy in year 4; if no advanced adenoma, repeat every 5 y |
| >5 Years posttreatmentb                       |
| • CEA not recommended                         |
| • Chest/abdominal/pelvic CT not recommended   |
| • Colonoscopy every 5 y starting 9 y after resection if no advanced adenoma |
| • Proctoscopy (rectal cancer only) not recommended |
| NOT recommended                               |
| • Routine blood tests (eg. CBC, liver function test) |
| • After 5 y, routine CEA monitoring           |
| • After 5 y, routine CT scans                 |
| • Routine use of PET/CT at any stage          |
| • PET scans are not considered an acceptable substitution for CT scans |
| Optimal timing unknown                        |
| • Screen survivors for breast, cervical, and prostate cancers as average risk according to American Cancer Society guidelines |
| • Counsel and treat patients with known or suspected HNPCC or FAP according to high-risk screening guidelines |

CBC indicates complete blood count; CEA, carcinoembryonic antigen; CT, computed tomography; FAP, familial adenomatous polyposis; H & P, history and physical; HNPCC, hereditary nonpolyposis colorectal cancer; PET, positron emission tomography. The only surveillance recommendation for stage I colon cancer is colonoscopy. The National Comprehensive Cancer Network rating indicates uniform NCCN consensus that the intervention is appropriate based on lower-level evidence. Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.2.2015 and Rectal Cancer Version 2.2015. © 2015 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.
3 years, CEA testing is recommended every 6 months when the potential exists for further therapeutic intervention of recurrent disease. After 5 years, routine CEA is not monitored.

**Recommendation 5:** Chest/abdominal/pelvic computed tomography should be performed every 12 months (stages I-II if at high risk for recurrence and stage III) for up to 5 years; routine positron emission tomography-computed tomography is not recommended at any stage and routine computed tomography is not recommended after 5 years. Level of evidence = 2A

In addition the NCCN recommends, for stage III cancer and those at high risk for recurrence, annual chest/abdomen/pelvis computed tomography (CT) scans are recommended annually for up to 5 years. After 5 years, routine CT scans are not recommended. Routine use of positron emission tomography (PET)/CT is not recommended in this setting.

In contrast to the NCCN recommendations, ASCO recommends CT scans of the abdomen and chest annually for only 3 years for CRC survivors. For rectal cancer survivors, a pelvic CT scan is also recommended, and the oncologist’s judgment should be used to determine the frequency of pelvic scans based on recurrence risk in patients (typically every 6–12 months for 2 or 3 years, then annually until 3–5 years after surgery). PET scans are not recommended as an acceptable substitution.

ASCO has endorsed the Cancer Care Ontario Clinical Practice Guideline on surveillance protocols for patients with stage II and III CRC. In the guideline, shorter intervals of follow-up are recommended for patients at higher risk of recurrence (eg, stage IIIC, genetic syndromes, and CEA fluctuations). A medical history, physical examination, and CEA testing should be performed every 3 to 6 months for 5 years. A shorter interval is considered earlier in the surveillance period, because 80% of recurrences occur in the first 2.0 to 2.5 years in patients with a high risk of recurrence. The ASCO panel noted the principles of conditional survival estimates, which are based on time already survived after diagnosis and treatment. Taking survival time into account allows for improved accuracy of prognostication. For CRC, there are very high conditional survival rates at 4 to 5 years after treatment, lending evidence to support “stop dates” for surveillance protocols, especially because disease-specific survival is very good after 3 years without clinical, serologic, or radiologic evidence of disease recurrence.

In contrast to the NCCN recommendations, ASCO recommends CT scans of the abdomen and chest annually for only 3 years for CRC survivors. For rectal cancer survivors, a pelvic CT scan is also recommended, and the oncologist’s judgment should be used to determine the frequency of pelvic scans based on recurrence risk in patients (typically every 6–12 months for 2 or 3 years then annually until 3–5 years after surgery). PET scans are not considered an acceptable substitution.

**Screening for Second Primary Cancers**

**Recommendation 6:** CRC survivors should receive age-appropriate and gender-appropriate screening for patients with an average risk, except for female CRC survivors with Lynch syndrome (see Recommendation 7). Level of evidence = 2A

Screening for other malignancies, such as breast, cervical, prostate, or lung cancer, should be continued for CRC survivors according to age, gender, and risk factor criteria as per ACS guidelines. Table 2 summarizes the ACS screening recommendations for each of these cancers among average-risk individuals. In addition, some CRC survivors have an elevated risk of second primary cancers because of genetic factors and, thus, should undergo a more intensive regimen of screening.

Patients should not undergo cancer screening without first having a discussion with their primary care clinician about the risks, benefits, and limitations of the particular screening modalities and the implications of positive screening tests. This is as true for cancer survivors as it is for the general population. In considering the benefits of screening, primary care clinicians and patients should consider the patient’s overall health and life expectancy and whether any patient characteristics place the patient at elevated risk for a specific cancer type.

When possible, primary care clinicians should take the opportunity to acknowledge to patients when professional society recommendations disagree. Such discordance is most notable in the cases of breast and prostate cancer screening recommendations. Although the ACS currently recommends annual mammography beginning at age 40 years, updated guidelines are expected to be released later this year. The US Preventive Services Task Force (USPSTF) provides a far more conservative recommendation of beginning biennial mammography at age 50 years and does not support teaching breast self-examination at the time of this writing. Given an average age of CRC diagnosis of 68 years, it is likely that mammographic screening will be indicated for a substantial portion of female survivors regardless of the guideline followed. For males, the USPSTF recommends against routine prostate cancer screening. The ACS suggests that patients and their primary care clinicians make the decision regarding whether to screen based on an adequate understanding of the harms (overdiagnosis, overtreatment, false-positive tests, complications of testing and treatment), benefits (decreased likelihood of late-stage diagnosis of prostate cancer), and uncertainties of screening.
TABLE 2. American Cancer Society Recommendations for the Early Detection of Breast, Cervix, Colorectal, Endometrial, and Prostate Cancer in Average Risk Asymptomatic Adults and Lung Cancer in High Risk Asymptomatic Adults

| CANCER SITE | POPULATION | TEST OR PROCEDURE | FREQUENCY |
|-------------|------------|-------------------|-----------|
| Breast      | Women ages ≥20 y | Breast self-examination (BSE) | It is acceptable for women to choose not to do BSE or to do BSE regularly (monthly) or irregularly; beginning in their early 20s, women should be told about the benefits and limitations of BSE; whether or not a woman ever performs BSE, the importance of prompt reporting of any new breast symptoms to a health professional should be emphasized; women who choose to do BSE should receive instruction and have their technique reviewed on the occasion of a periodic health examination |
|             |            | Clinical breast examination (CBE) | For women in their 20s and 30s, it is recommended that CBES be part of a periodic health examination, preferably at least every 3 years; asymptomatic women aged ≥40 y should continue to receive a CBE as part of a periodic health examination |
|             |            | Mammmography | Begin annual mammography at age 40 y |
| Cervix      | Women, ages 21-65 y | Pap test and HPV DNA test | Cervical cancer screening should begin at age 21 y; for women ages 21-29 y, screening should be done every 3 y with conventional or liquid-based Pap tests; for women ages 30-65 y, screening should be done every 5 y with both the HPV test and the Pap test (preferred) or every 3 y with the Pap test alone (acceptable); women aged >65 y who have had ≥3 consecutive negative Pap tests or ≥2 consecutive negative HPV and Pap tests within the last 10 y, with the most recent test occurring in the last 5 y, and women who have had a total hysterectomy (for a benign condition) should stop cervical cancer screening; women at any age should not be screened annually by any screening method |
| Colorectal  | Men and women, ages ≥50 y | Guaiac-based fecal occult blood test (gFOBT) with at least 50% test sensitivity for cancer, or fecal immunochemical test (FIT) with at least 50% test sensitivity for cancer, or | Annual starting at age 50 y; testing at home with adherence to manufacturer’s recommendation for collection techniques and number of samples is recommended; FOBT with the single stool sample collected on the clinician’s fingertip during a digital rectal examination in the health care setting is not recommended; guaiac-based toilet bowl FOBT tests also are not recommended; compared with guaiac-based tests for the detection of occult blood, immunochemical tests are more patient-friendly and are likely to have equal or better sensitivity and specificity; there is no justification for repeating FOBT in response to an initial positive finding |
|             |            | Stool DNA test, or | Every 3 y, starting at age 50 y |
|             |            | Flexible sigmoidoscopy (FSIG), or | Every 5 y, starting at age 50 y; FSIG can be performed alone, or consideration can be given to combining FSIG performed every 5 y with a highly sensitive gFOBT or FIT performed annually |
|             |            | Double-contrast barium enema, or | Every 5 y, starting at age 50 y |
|             |            | Colonoscopy, or | Every 10 y, starting at age 50 y |
|             |            | CT colonography | Every 5 y, starting at age 50 y |
| Endometrial | Women, at menopause | | At the time of menopause, women at average risk should be informed about risks and symptoms of endometrial cancer and strongly encouraged to report any unexpected bleeding or spotting to their physicians |
| Lung        | Current or former smokers (quit within past 15 y) ages 55-74 y in good health with at least a 30 pack-year history | Low-dose helical CT (LDCT) | Clinicians with access to high-volume, high-quality lung cancer screening and treatment centers should initiate a discussion about annual lung cancer screening with apparently healthy patients ages 55-74 y who have at least a 30 pack-year smoking history and who currently smoke or have quit within the past 15 y; a process of informed and shared decision making with a clinician related to the potential benefits, limitations, and harms associated with screening for lung cancer with LDCT should occur before any decision is made to initiate annual lung cancer screening; smoking-cessation counseling remains a high priority for clinical attention in discussions with current smokers, who should be informed of their continuing risk of lung cancer; screening should not be viewed as an alternative to smoking cessation |
| Prostate    | Men, ages ≥50 y | Digital rectal examination and prostate-specific antigen test | Men who have at least a 10-y life expectancy should have an opportunity to make an informed decision with their health care provider about whether to be screened for prostate cancer after receiving information about the potential benefits, risks, and uncertainties associated with prostate cancer screening; prostate cancer screening should not occur without an informed decision-making process |

CT, computed tomography; gFOBT, guaiac fecal blood occult blood test; Pap, Papanicolaou. *Beginning at age 40 years, annual CBE ideally should be performed before mammography.
Women with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPPC), constitute a group with a clearly elevated risk for subsequent cancer diagnoses. These women have a 27% to 71% lifetime risk of endometrial cancer—greater than that of CRC—and a 3% to 14% lifetime risk of ovarian cancer. Therefore, based on expert opinion, the ACS suggests that women who are confirmed carriers of a Lynch syndrome mutation or who are likely carriers based on mutation status or incidence patterns of family members begin screening with annual endometrial biopsy at age 35 years.

Regardless of HNPPC or CRC status, endometrial sampling has a sensitivity of 99.6% in postmenopausal women and 91% in premenopausal women for the detection of endometrial carcinoma and is minimally invasive. Transvaginal ultrasound (TVUS) alone is not a reliable screen for endometrial cancer in premenopausal women given highly variable endometrial thickness during the menstrual cycle. The sensitivity of TVUS in asymptomatic postmenopausal women is approximately 83%, which is considerably lower than that of biopsy in this group, although it is also thought to be useful for the detection of ovarian neoplasms. Evidence does support the effectiveness of prophylactic hysterectomy and oophorectomy as a means of prevention for both endometrial and ovarian cancer in women with HNPPC. The decision as to whether to pursue this option should be made after careful discussion with the patient of the risks of surgery and future fertility plans. Finally, endometrial biopsy should be performed in any woman with Lynch syndrome who reports irregular or postmenopausal vaginal bleeding.

Assessment and Management of Physical and Psychosocial Long-Term and Late Effects of CRC and Its Treatment

The risk of physical long-term and late effects after therapy for CRC is associated with several factors, including: 1) type of primary tumor, 2) type of chemotherapy, 3) duration and dose of treatment(s) (increasing cumulative dose and duration of therapy increases the potential risk), and 4) age of patient during treatment (Table 3: Guidelines for the Assessment and Management of Physical and Psychosocial Long-Term and Late Effects). Commonly used chemotherapy and biotherapy agents used to treat CRC include 5-fluorouracil (5-FU), oxaliplatin, and capcitabine. These drugs have been administered to patients in different combinations and at various dosages and lengths of time, which may relate to the possible long-term and late effects. Primary care clinicians should refer to the patient’s cancer treatment summary for the specific drugs and doses. Table 4 lists potential physical and psychosocial long-term and late effects associated with surgery, radiation, and chemotherapy, which are described in the rest of this section (Table 4: Summary of Potential Long-Term and Late Effects of Colorectal Cancer and Its Treatment).

Bowel/Gastrointestinal Issues

Chronic diarrhea, ie, diarrhea lasting longer than 4 weeks that limits activities and negatively impacts QoL, is one of the most common long-term conditions, affecting almost half of CRC survivors. Among patients who undergo low anterior resection (LAR) for rectal cancer and other lower surgical anastomoses, bowel dysfunction is common, including increased stool frequency, bowel incontinence, and perianal irritation; decreased stool and flatus discrimination; and more incomplete evacuations. Rates of bowel problems are significantly increased in rectal cancer survivors treated with pelvic radiation, regardless of whether it was administered preoperatively or postoperatively.

Empirical support to guide the optimal management of bowel problems is limited (level III evidence). However, antidiarrheal medications, such as loperamide (Imodium) or diphenoxylate/atropine (Lomotil), are common first-line treatment for chronic diarrhea after radiation therapy. Dietary adjustments, especially the elimination of raw vegetables, can be of benefit. Low-fat diets, probiotic supplementation, and elemental diets also may be beneficial among patients treated with pelvic radiation.

Persistent symptoms may necessitate referral to gastroenterology. Options for the treatment of fecal incontinence include medical therapy, such as bulking agents or antidiarrheal medications to reduce stool frequency and improve stool consistency, biofeedback therapy to improve control of the pelvic floor and abdominal wall musculature, and surgery.

Cardiovascular Effects

The risk of cardiovascular morbidity does not appear to be increased in long-term CRC survivors. In a large British cohort study, Khan and colleagues did not observe an excess risk of heart failure or coronary artery disease among CRC survivors. Nevertheless, there are
### TABLE 3. Guidelines for the Assessment and Management of Physical and Psychosocial Long-Term and Late Effects

| GUIDELINE                             | LEVEL OF EVIDENCE* |
|---------------------------------------|--------------------|
| **Bowel/gastrointestinal issues**     |                    |
| - Discuss frequency and/or urgency of bowel movements or loose bowels | III                |
| - Assess for rectal ulceration and/or bleeding |                    |
| - Assess for rectal emptying problems/incontinence |                    |
| - Discuss bowel function and symptoms (eg, rectal bleeding) with survivors |                    |
| - Refer survivors with persistent rectal symptoms (eg, bleeding, sphincter dysfunction, rectal urgency and frequency) to the appropriate specialist |        |
| **Cognitive function**                | 0                  |
| - Screen for problems such as depression and anxiety that might worsen cognition and refer for treatment |        |
| - Refer patients with a positive screen for formal neurocognitive training |                    |
| **Dental/oral**                       | 0                  |
| - Monitor for loss of taste and dry mouth |                    |
| - Recommend saliva substitutes or medications to provide symptom relief |        |
| - Recommend attention to good oral hygiene (flossing, brushing with fluoride toothpaste, regular dental care) |            |
| **Distress/depression/anxiety**       | 1/0 (psychosocial screen), IIA (stoma) |
| - Level of risk: Higher for those with a stoma and those with sexual dysfunction |        |
| - Screen for distress/depression/anxiety periodically (at least annually) using a simple screening tool, such as the Distress Thermometer |        |
| - Manage distress/depression using in-office counseling resources, pharmacotherapy, or prescribe exercise as appropriate |        |
| - If office-based counseling and treatment are insufficient, refer survivors experiencing distress/depression for further evaluation and or treatment by appropriate specialists |        |
| **Fatigue**                           | 1                  |
| - Assess with a validated instrument such as the MDASI, BFI, FACT-G7, or FACT-C |        |
| - Recommend psychosocial support interventions and/or mind-body interventions |        |
| - Recommend 150 minutes of physical activity per week plus strength training per ACS Nutrition & Physical Activity Guidelines for Cancer Survivors |        |
| - Recommend optimizing nutrition per ACS Nutrition & Physical Activity Guidelines for Cancer Survivors |        |
| - For chronic fatigue, refer to rehabilitation |        |
| **Neuropathy**                        | 0                  |
| - Focus on prevention; strong evidence for therapy is lacking |        |
| - Assess with Total Neuropathy Score or other validated tool for patients receiving oxaliplatin |        |
| - Higher risk criteria                 |                    |
| o Patients who receive a cumulative dose of >900 mg/m² are at higher risk |        |
| o Patients with preexisting neuropathy, alcoholism, and diabetes mellitus |        |
| - Treat with duloxetine (moderate recommendation) |        |
| - No evidence to support tricyclic antidepressants, gabapentin, or topical gel containing baclofen, amitriptyline HCl, or ketamine; but these therapies have been used for other neuropathic pain conditions |        |
| - Refer to rehabilitation and pain management as needed |        |
| **Ostomy/stoma**                      | 1                  |
| - Rectal cancer survivors are more likely to need a permanent stoma than colon cancer survivors |        |
### TABLE 3. Continued

| GUIDELINE                                                                 | LEVEL OF EVIDENCEa |
|---------------------------------------------------------------------------|--------------------|
| • Monitor and manage sexual dysfunction as needed                          |                    |
| • Monitor and refer for psychosocial support for increased distress, depression and anxiety, and poorer quality of life |                    |
| Pain                                                                      |                    |
| • Assess for incisional hernia with complications                           | I                  |
| • Consider opioid analgesics, use of pain management services, if available; incorporation of behavioral interventions/physical activity and/or rehabilitation/physical therapy have demonstrated efficacy for pain control in systematic reviews in other cancers or pain syndromes |                    |
| Sexual function/fertility                                                  | 0, IA (oral phosphodiesterase-5 inhibitors in men), IC (vaginal moisturizers and lubricants for women) |
| • Level of risk: Affects a small percentage of CRC survivors               |                    |
| • Higher risk criterion: Women who receive pelvic radiotherapy             |                    |
| • Discuss urogenital dysfunction/sexual dysfunction (eg, erectile dysfunction, dyspareunia, vaginal dryness, incontinence) |                    |
| • Men who receive pelvic radiotherapy or oxaliplatin may be at higher risk for gonadotoxicity (limited evidence) |                    |
| o Evaluate for Leydig cell dysfunction                                     |                    |
| o Initiate testosterone replacement as indicated                           |                    |
| • Women survivors of rectal cancer with a stoma are at higher risk for vaginal dryness and dyspareunia |                    |
| o Recommend vaginal moisturizers and water or silicone-based lubricants during intercourse |                    |
| • For men with erectile dysfunction, treat with oral phosphodiesterase-5 inhibitors |                    |
| • Sexual dysfunction is correlated with greater psychosocial distress—see recommendation 12 for management recommendations |                    |
| Urinary/bladder issues                                                     | IC                 |
| Surgery                                                                   |                    |
| • Assess for stress, urge, and overflow urinary incontinence in patients who underwent surgery |                    |
| • Recommend Kegel exercises for stress incontinence unless denervation occurred during surgery |                    |
| • Recommend anticholinergic drugs for stress incontinence                  |                    |
| • Recommend antimuscarinic drugs for urge or mixed incontinence            |                    |
| • Patients with hypocontractile bladders may require catheterization      |                    |
| • Refer patients with prolonged urinary retention postoperatively to urologist |                    |
| Radiation                                                                 |                    |
| • Assess for incontinence, frequency, urgency, dysuria, or hematuria in patients who underwent surgery |                    |
| • Recommend limiting caffeine and fluid intake and avoiding foods that irritate the bladder, such as citrus and tomatoes, for irritative symptoms |                    |
| • Refer patients with persistent hematuria to a urologist for cystoscopy to investigate secondary causes |                    |

ACS indicates American Cancer Society; BFI, Brief Fatigue Inventory; CRC, colorectal cancer; FACT-C, Functional Assessment of Cancer Therapy-Colorectal Cancer; FACT G7, 7-item Functional Assessment of Cancer Therapy-General (for patients with any tumor type); MDASI, MD Anderson Symptom Inventory. *Levels of evidence include: I, meta analyses of randomized controlled trials (RCTs); IA, RCT of colorectal cancer survivors; IB, RCT based on cancer survivors across multiple sites; IC, RCT based not on cancer survivors but on the general population experiencing a specific long-term or late effect (eg, chronic diarrhea, sexual dysfunction, etc); IIA, non-RCT based on colorectal cancer survivors; IIB, non-RCT based on cancer survivors across multiple sites; IIC, non-RCT based not on cancer survivors but on the general population experiencing a specific long-term or late effect (eg, chronic diarrhea, sexual dysfunction, etc); III, case study; and 0, expert opinion, observation, clinical practice, literature review, or pilot study.
some important aspects regarding the cardiovascular system in CRC survivors that should be noted. It has long been recognized that 5-FU can induce acute endothelial dysfunction, generally manifested as chest pain but rarely resulting in an acute myocardial infarction. Therapy with capecitabine, a metabolite of 5-FU, has also rarely resulted in acute myocardial infarction. Individuals with preexisting coronary artery disease are at increased risk for this acute toxicity. Fortunately, once therapy is complete, there does not appear to be any lasting cardiovascular risk attributable to these 2 antimitabolite agents. To date, there has not been convincing evidence, beyond occasional case reports, of acute or long-term cardiotoxicity associated with oxaliplatin therapy.

Although adjuvant therapy for CRC appears to have a relatively low risk for acute or chronic cardiotoxicity, there are indirect pathways within a subset of CRC survivors that may hasten the progression of cardiovascular disease (CVD). Obesity and sedentary lifestyles are associated with an increased risk of CRC. Although adjuvant therapy for CRC appears to have a relatively low risk for acute or chronic cardiotoxicity, there are indirect pathways within a subset of CRC survivors that may hasten the progression of cardiovascular disease (CVD). Obesity and sedentary lifestyles are associated with an increased risk of CRC. Thus, it should not be surprising that, in a large, population-based cohort study, the risk of CVD in CRC survivors is higher than in the general population.
Hawkes and colleagues found that CVD was diagnosed by 36 months after the cancer diagnosis in 16% of survivors without known preexisting disease. The primary risk factors for developing hypertension, diabetes, and ischemic heart disease were obesity at the time of CRC diagnosis and persistent sedentary lifestyles. In a recent study, Cramer et al reported that CRC survivors, regardless of whether or not they were treated with adjuvant therapy, had substantially reduced exercise capacity. This theme of diminished exercise capacity and cardiorespiratory fitness is common across cancer groups and is a key catalyst, when combined with preexisting obesity and lifelong sedentary behaviors, in the development of CVD. Thus, it is imperative that primary care clinicians counsel CRC survivors regarding the well-studied adverse impact of obesity and sedentary behaviors and the critical need for modifications in what often have been lifelong habits.

Cognitive Function

Recommendation 10: (a) Screen for cognitive problems, (b) assess for depression and anxiety that may worsen cognition, and (c) refer for treatment. Level of evidence = O

Patients have reported changes in cognitive function attributed to cancer treatment with chemotherapy although the mechanism is still not well understood. The majority of studies focus on breast cancer patients, so there is a paucity of data on other cancers; however, a national cross-sectional study looked at self-reported memory problems and found that patients who had undergone treatment for cancer were 40% more likely to report memory problems than those without cancer, regardless of the type of cancer or treatment. In a prospective, population-based cohort of CRC survivors, chemotherapy was associated with worsening cognitive function, particularly for individuals younger than 70 years.

The symptoms reported by patients who complain of cognitive decline vary but may include decreased executive functioning skills, slower processing time or reaction response, diminished organizational skills, loss of language or math skills, and/or difficulty with concentration or attention. These often translate into lower health-related QoL scores, especially as patients transition back to work. These symptoms can be difficult to interpret clinically, because there is often discordance between the subjective complaints of memory loss and objective testing. Memory impairment may be confounded by physical symptoms associated with treatment, such as fatigue or pain, as well as mental health concerns (stress, anxiety, or depression). The NCCN Guidelines for Survivorship suggest screening for treatable causes that may worsen cognitive impairment, such as depression and anxiety, although data are lacking for evidence-based recommendations regarding routine screening for cognitive decline in this population.

For patients who report a change in memory or cognitive function, there are a few tools, including the Mini Mental State Exam (MMSE) or the Functional Assessment of Cancer Therapy Cognitive (FACT-Cog), which may be used for screening. A caveat of these screening tools is that they are not sensitive for determining deficits in executive functioning, so they may underestimate cognitive decline. For positive screens, the next step would be a referral for formal neurocognitive testing. Neurocognitive testing can quantify and define specific problems that may impact activities of daily living or work, which can be helpful for patients to understand.

Unfortunately, there are no proven treatments for cognitive impairment related to cancer treatment; however, referral for cognitive rehabilitation strategies, eg, those used for patients after strokes, may be helpful, and studies testing the effects of physical activity on cognition are ongoing.

Dental/Oral

Recommendation 11: (a) Ask CRC survivors if they are experiencing symptoms of mucositis, loss of taste, or dry mouth and (b) treat similar to population with average risk. Level of evidence = O

In a prospective cohort study of CRC survivors, loss of taste and dry mouth were identified as significant late effects in patients who had received chemotherapy as measured by QoL scores 5 years posttreatment. Dry mouth can lead to tooth decay, mouth sores, or gum disease. Empirical support for recommendations is lacking, although good oral hygiene (brushing teeth with fluoride-containing toothpaste, flossing regularly, etc) can prevent these complications. However, if the symptoms are severe, then referral to a dentist is recommended for further evaluation and management.

Distress/Depression/Anxiety

Recommendation 12: (a) Screen CRC survivors for psychosocial distress, depression, and anxiety using a validated screening tool; special attention should be paid to survivors with a stoma and those who report sexual dysfunction. Level of evidence = I/O (psychosocial screen), IIA (stoma)

(b) Refer patients to the appropriate mental health professionals or resources in the community as indicated; in addition, follow-up with the survivor to assess adherence and ensure that the need was met, identify potential barriers, and seek alternative approaches as needed. Level of evidence = I

Where appropriate, these guidelines leverage the ASCO guideline adaptation of a Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer.
Many cancer survivors report ongoing difficulties in recovery and returning to “normal” after treatment.\textsuperscript{16,17,19} Some survivors of cancer experience fear of recurrence,\textsuperscript{56} contributing to significant mental health problems for which they already have an increased risk, including distress, depression, and anxiety.\textsuperscript{57,58} Prevalence estimates for anxiety, depression, and distress in cancer survivors are widely variable as a result of inconsistency in the use of measurement tools and differences in methodological approaches, such as the choice of comparators from the general population. However, among cancer survivors generally, the estimated prevalence of anxiety and depression is 17.9\% and 11.6\%, respectively.\textsuperscript{59} Among CRC survivors specifically, an estimated 24\% report depression scores on a standard screening tool high enough to warrant evaluation for clinical depression.\textsuperscript{60} Furthermore, 8\% of CRC survivors experience distress severe enough to require follow-up.\textsuperscript{60}

Studies suggest that CRC patients and survivors fitted with stoma devices report higher levels of depression and anxiety, poorer social functioning, more problems with body image, and more side effects from chemotherapy compared with those without a stoma. For example, a prospective study of 249 CRC patients assessed at 3, 6, 12, and 24 months reported poorer QoL in stoma patients, who demonstrated significantly greater impairments on sexual functioning and diminished capacity to perform roles.\textsuperscript{61} These problems were most pronounced among male CRC survivors with stomas. The timing of the stoma procedure was an important factor; patients whose stoma was made during the primary procedure fared better than patients whose stoma was made some time after the initial operation.\textsuperscript{61} Thus, it is recommended that primary care clinicians pay particular attention to CRC survivors with a stoma, especially those whose stoma was made later in the treatment trajectory and male survivors, who may experience significantly greater impairments in functioning and overall QoL.

To provide timely and appropriate support for their patients with a history of CRC, primary care clinicians should be familiar with the mental health concerns they may experience, the tools to screen for and assess these problems, and the resources at their disposal to care for their patients. Primary mental health issues revolve around fear of recurrence,\textsuperscript{56} distress, depression, and anxiety. The NCCN defines distress as an emotionally unpleasant, multifactorial experience of a psychological (cognitive, behavioral, emotional), spiritual, and/or social nature that may interfere with a patient’s ability to cope effectively with cancer, its physical symptoms and its treatment.\textsuperscript{62} A well-known tool for initial screening is the Distress Thermometer (DIS-A) (Fig. 2: NCCN Distress Thermometer and Problem List), which is similar to the rating scale used to measure pain on a scale from 0 (no distress) to 10 (extreme distress), in which a score of 4 or higher\textsuperscript{63} suggests a level of distress that has clinical significance. In addition, a 38-item Problem List (Fig. 2) asks patients to identify their problems in 5 categories: practical, family, emotional, spiritual/religious, and physical. These tools are available from the NCCN Guidelines for Distress Management.\textsuperscript{62} Similarly, the Survivor Unmet Needs Survey (SUNS) and the Short-Form SUNS (SF-SUNS) can be used to distinguish between problems which survivors experience and problems which they desire help in managing across a range of life areas, including financial concerns, information and access, and continuity of care.\textsuperscript{64,65}

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest, whereas anxiety is an intense, excessive, and persistent worry and fear about everyday situations.\textsuperscript{66-68} Both depression and anxiety can initially be screened using a variety of instruments. One commonly used measure is the validated Hospital Anxiety and Depression Scale (HADS). The HADS is a 14-item self-report instrument that consists of 2 distinct scales, one for depression and one for anxiety, each scored from 0 to 3, with a final score between 0 and 21. A score of 9 or higher on either scale suggests a level of depression or anxiety that has clinical significance.\textsuperscript{69}

Another validated instrument that may be used to screen for depression in cancer survivors is the Center for Epidemiologic Studies Depression Scale (CES-D) (a more recent version of the scale is available online at cesd-r.com). This instrument has 20 questions, each scored from 0 to 3, concerning emotions and feelings over the past week.\textsuperscript{70,71} A score of 16 or higher suggests a level of depression that has clinical significance.\textsuperscript{72} The tool identifies significantly more clinical cases than the HADS in similar populations, including both true cases and false-positives, with more variable results.\textsuperscript{72}

Treatment of anxiety and depression is effective in people with cancer; therefore, if a patient has a clinically significant score on any of the previously discussed instruments, it is recommended that primary care clinicians refer and/or connect patients to the appropriate psychosocial oncology specialists, mental health professionals, and/or resources in the community.\textsuperscript{7} After referring to the appropriate resource(s), primary care clinicians should follow-up with patients to check their adherence. If a patient has difficulties adhering to recommendations, then primary care clinicians should work to help identify these challenges and find a way for the patient to overcome these obstacles before discussing alternative interventions to help the patient comply.\textsuperscript{11} The American Psychosocial Oncology Society (apos.org) can help primary clinicians identify these resources. The efficacy of psychosocial support for patients, including those with CRC, is supported by one RCT showing a survival benefit for those who received...
these services. Other evidence for psychosocial interventions comes from observational studies linking poor emotional well-being and survival. Exercise has also been shown to improve well-being in cancer survivors, as documented in a Cochrane review.

Fatigue
Cancer-related fatigue (CRF) is a potential long-term effect of chemotherapy that is prevalent in cancer survivors and often causes significant disruption in functioning and QoL. NCCN defines fatigue as a persistent, distressing, subjective sense of emotional, physical, and/or cognitive exhaustion or tiredness related to cancer or its treatment that is not proportional to a patient’s recent activity and interferes with their usual functioning. Fatigue is reported by patients more frequently than any other symptom during the course of cancer and its treatment and is often the most severe and most bothersome symptom reported because of its persistence and interference with daily activities.

In a multicenter study of cancer survivors (patients with complete remission or no evidence of disease and not currently receiving treatment), researchers observed a 23% prevalence of fatigue in short-term (<5 years; n = 117) and 43% in long-term (≥5 years; n = 23) CRC survivors. Twenty-seven percent of CRC survivors reported moderate to severe fatigue. Twenty-nine percent of cancer survivors (for all 4 cancer types combined) reported moderate/severe fatigue that was associated with poor performance status and a history of depression. Gender was not identified as a significant factor among CRC survivors.

Recommendation 13: (a) Assess with a validated fatigue instrument, (b) recommend physical activity similar to that recommended for the general population, and (c) refer to specialists for psychosocial support or rehabilitation as indicated. Level of evidence = I
clinicians should screen every patient for the presence of CRF and gauge its severity periodically throughout long-term survivorship. If present, fatigue should be assessed quantitatively on a scale from 0 (no fatigue) to 10 (worst fatigue imaginable); those patients with a severity of more than 4 should be further evaluated by a history and physical examination. For patients who report moderate to severe fatigue, comprehensive assessment should be conducted, and medical and treatable contributing factors addressed.

CRF typically has several different contributing factors in any one patient. Primary care clinicians should work with patients and caregivers to improve assessment and identify management strategies. Managing CRF includes consistent, reliable screening and assessment using a validated instrument and patient-report; treatment of comorbidities that may be contributing factors; and multimodal and individually tailored interventions (eg, exercise, psychoeducational and self-management strategies, efforts to manage concurrent symptoms and improve sleep quality, medications, and complementary therapies) to improve patient-reported symptoms. Patient report is important to fatigue assessment. Fatigue management should be initiated when patients rate their fatigue as moderate or severe. A single screening question may be efficient to quickly screen for fatigue in clinical practice to identify patients who may benefit from further multifactorial evaluation. Various patient self-report measures of CRF are available.

### FACT-G7 (Version 4)

Below is a list of statements that other people with your illness have said are important. Please circle or mark one number per line to indicate your response as it applies to the past 7 days.

| GP1 | I have a lack of energy | Not at all | A little bit | Some-what | Quite a bit | Very much |
|-----|-------------------------|------------|-------------|-----------|------------|-----------|
| GP2 | I have pain | 0 | 1 | 2 | 3 | 4 |
| GP3 | I have nausea | 0 | 1 | 2 | 3 | 4 |
| GP4 | I worry that my condition will get worse | 0 | 1 | 2 | 3 | 4 |
| GP5 | I am sleeping well | 0 | 1 | 2 | 3 | 4 |
| GP6 | I am able to enjoy life | 0 | 1 | 2 | 3 | 4 |
| GP7 | I am content with the quality of my life right now | 0 | 1 | 2 | 3 | 4 |

**FIGURE 3.** The 7-item Functional Assessment of Cancer Therapy-General (FACT-G7), Version 4. The FACT-G7 is a general measure for the functional assessment of cancer therapy to be used with patients who have any tumor type. Reprinted from: Cella DF, Tulsky DS, Gray G, Sarafian B, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. *J Clin Oncol*. 1993;11:570-579. The FACT-G7 is a copyrighted instrument, reprinted with permission from FACIT.org (facit.org/FACITOrg/Questionnaires).
For chronic CRF, primary care clinicians should refer survivors to rehabilitative specialists to address lingering fatigue and provide supportive care recommendations. General supportive care recommendations for patients with fatigue include optimizing nutritional status and preventing weight loss, balancing rest with physical activity, and attention-restoring activities such as exposure to natural environments and pleasant distractions like music.\textsuperscript{76}

Neuropathy

Chemotherapy-induced peripheral neuropathy (C-IPN) is a potential long-term effect of neurotoxicity caused by chemotherapeutic agents that can lead to permanent symptoms and disability in more than 40% of cancer survivors, negatively affecting QoL.\textsuperscript{98} Oxaliplatin is commonly considered standard therapy in CRC adjuvant chemotherapy regimens. Oxaliplatin-induced peripheral neuropathy (O-IPN) is common among survivors one or more years after treatment.\textsuperscript{99-103} Cumulative O-IPN is reported to be partially reversible in approximately 80% of patients and completely resolves in approximately 40% at 6 to 8 months posttreatment. Chronic, cumulative O-IPN persists posttreatment, and severe O-IPN resolves approximately 13 weeks posttreatment in most patients.\textsuperscript{99,104} Signs and symptoms may continue to develop and worsen for an additional 2 to 6 months posttreatment, also known as 

\textit{coasting}.\textsuperscript{12,105} Sensory nerve dysfunction is most common. The large sensory nerves are affected, leading to symptoms of paresthesias, such as “pins and needles” or tingling, numbness, pressure, cold, and warmth that are experienced in the absence of a stimulus; dysesthesias or distortion of sensory perception resulting in an abnormal and unpleasant sensation; and numbness in the hands and feet.\textsuperscript{106-108} Clinical examination may uncover impairment in perception of touch, vibration, and proprioception. Nerve endings in the hands and feet are usually affected earliest by neurotoxicity in a symmetrical, length-dependent manner, affecting the longest nerve fibers in the body first. Disabling symptoms like sensory ataxia, pain, and severe numbness can interfere with functional ability and QoL.

\textbf{Recommendation 14: (a) Assess with Total Neuropathy Score or other validated tool for CRC survivors who received oxaliplatin, and (b) refer to rehabilitation and pain management specialists as indicated. Level of evidence = 0}  

Preexisting factors that may increase patient risk for developing O-IPN include preexisting neuropathy, alcoholism, and diabetes mellitus.\textsuperscript{99,100,109} A higher cumulative drug dose is a possible indicator for developing long-term O-IPN. A descriptive study reported that persistent grade 2 and 3 O-IPN was more common in patients who received a cumulative dose of more than 900 mg/m\textsuperscript{2}, suggesting the influence of oxaliplatin administration on long-term O-IPN.\textsuperscript{99,110}

Currently, no standardized assessment tool or questionnaire for O-IPN has been used in studies of O-IPN. The National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE), or “common toxicity criteria” (toxicity graded as mild [grade 1], moderate [grade 2], or severe [grade 3]),\textsuperscript{108} has been applied more widely in addition to the FACT/Gynecologic Oncology Group Oxaliplatin-Specific Neuropathy questionnaire (FACT/GOG-Ntx), a reliable and valid instrument for assessing the impact of neuropathy on health-related QoL; a neuropathic symptom questionnaire; and neurophysiological examinations (eg, nerve-conduction studies).\textsuperscript{99,107,111} Use of the Total Neuropathy Score (TNSc) (Fig. 4), which does not require specialized equipment or training, may be more suitable for clinical practice.

Strong evidence for standard therapy or neuroprotective strategy (eg, topical agents, antidepressants, and or antiepileptics) for O-IPN is currently lacking. Patient assessment for preexisting risk factors prior to treatment is key to preventing O-IPN by identifying patients who may be at increased risk of developing severe or persistent forms of O-IPN.\textsuperscript{99}

Although C-IPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel that contains baclofen, amitriptyline HCl, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the other limited C-IPN treatment options.\textsuperscript{12}

To treat existing C-IPN, the best available data support a moderate recommendation for treatment with duloxetine. The effect of duloxetine was studied in a randomized, placebo-controlled, cross-over trial of 231 patients with C-IPN. Patients received 30 mg of duloxetine or placebo for the first week and 60 mg of duloxetine or placebo for 4 more weeks. Patients who received duloxetine reported a significant decrease in average pain compared with those who received placebo (\(P = .003\)). In addition to a decrease in pain, data from the trial also supported that duloxetine decreased numbness and tingling symptoms.\textsuperscript{12,112}

Primary care clinicians should refer survivors for rehabilitative medicine treatments, including physical therapy and pain management, as needed. For disabling, chronic C-IPN, primary care clinicians should refer survivors to neurology or to occupational and physical therapy.\textsuperscript{113}

\textbf{Ostomy/Stoma}

\textbf{Recommendation 15: For CRC survivors with a stoma, (a) monitor for sexual dysfunction, distress, depression, anxiety, and QoL; (b) refer to specialists for support as indicated. Level of evidence = 1}  

Colon cancer survivors are less likely than rectal cancer survivors to need a permanent stoma. One of the challenges
CRC survivors face relates to caring for the ostomy and appliances. These challenges include routine ostomy care; achieving bowel regularity; issues with leakage, gas, and odor; and skin irritations at the ostomy site. Examples of dealing with the ostomy and appliances include finding the right equipment, equipment failures, and dietary changes and adaptations. Many of these issues can be addressed by a trained ostomy therapist. Patients with an ostomy may benefit from additional psychosocial support to adjust to and live with an ostomy appliance. The efficacy of psychosocial interventions that include patient education is supported by numerous RCTs and by a systematic review (level I evidence) documenting positive effects on stoma-related knowledge, health-related QoL, and cost-reduction.

### Pain

**Recommendation 16: Monitor patients who received pelvic irradiation for chronic proctitis, and manage symptoms as indicated. Level of evidence = I**

Chronic pain is one of the uncommon but important sequelae of CRC and its treatment. The most important risk factor for development of chronic pain is pelvic irradiation resulting in chronic proctitis. Chronic pain is known to contribute to functional limitation and negatively impacts QoL in CRC survivors. Although there are no specific guidelines for managing pain in the context of CRC survivorship, interventions with pharmacotherapy, including the use of opioid analgesics, utilization of pain-management services, if available, and the incorporation of behavioral interventions/physical activity and/or rehabilitation/physical therapy have demonstrated efficacy for pain control in systematic reviews of other cancers or pain syndromes (level I evidence).

### Sexual Function/Fertility

**Recommendation 17: (a) Address sexual function when managing CRC survivors. For CRC survivors of childbearing age who experience infertility due to treatment, (b) refer for psychosocial support: Level of evidence = 0, IA (oral phosphodiesterase-5 inhibitors in men), IC (vaginal moisturizers and lubricants for women)**

CRC is fairly uncommon during the reproductive years. The incidence of CRC is 3.3 and 3.8 per 100,000 persons for females and males, respectively, in the US between ages 15 and 39 years. As of 2008, it was estimated there were about 27,000 CRC survivors in the US who were age 44 years or younger. Reflecting the increasing incidence of CRC as individuals age, over half of this estimate included survivors between ages 40 and 44 years.

---

### Table: Total neuropathy score

| Parameter                        | Score |
|----------------------------------|-------|
| QST = quantitative sensory test; ULN = upper limit of normal; LLN = lower limit of normal. |       |
| Sensory symptoms                 | 0     |
|                                  | 1     |
|                                  | 2     |
|                                  | 3     |
|                                  | 4     |
| Motor symptoms                   |       |
|                                  |       |
| Autonomic symptoms, n           |       |
| Pin sensitivity                  |       |
| Vibration sensibility            |       |
| Strength                         |       |
| Tendon reflexes                  |       |
| Vibration sensation (QST vibration) |       |
| Sural amplitude                  |       |
| Peroneal amplitude               |       |

---

**FIGURE 4. The Total Neuropathy Score. The total neuropathy score is a validated measure of peripheral nerve function. Reprinted from: Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. *Neurology.* 1999;53:1660, with permission from John’s Hopkins University and Wolters Kluwer Health, Inc.**
relatively small number of CRC survivors who are treated during their reproductive years, there have consequently been few studies evaluating gonadal function and infertility after therapy. The primary therapy associated with infertility in women with rectal cancer is pelvic radiotherapy. Even with contemporary approaches to minimize the radiation exposure to normal surrounding tissues, the ovaries often receive substantial doses unless they are surgically transposed before radiation. With a diminishing primordial follicle pool among women in their 30s and 40s, the doses of radiation necessary to induce acute ovarian failure are lower than the doses for women who received pelvic radiation as children or adolescents. In men, despite shielding of the testes, the dose of radiation is often enough to damage the germinal epithelium and cause azoospermia. In the treatment of other cancer types, 5-FU has not been shown to cause infertility in women or men. Oxaliplatin is moderately gonadotoxic. In a woman whose primordial follicle pool is diminished by age, treatment with oxaliplatin may induce ovarian failure and premature menopause, thereby causing infertility. Fertility rates in males do not appear to be substantially affected, although this remains an understudied area.

Although infertility affects a relatively small percentage of CRC survivors, sexual dysfunction is a problem that spans across the age spectrum. In general, sexual dysfunction is prevalent after treatment for CRC, particularly among rectal cancer survivors. Study in this area is quite complex. A substantial proportion of individuals are diagnosed with CRC at an age when sexual activity is beginning to wane. Thus, to interpret prevalence data or a change in sexual activity, it is important to have a similarly aged noncancer population. Adding to the complexity of studies, surgical and radiation techniques have evolved, often aimed at reducing long-term outcomes such as sexual dysfunction while providing adequate local control of the tumor. For example, in the mid-1980s, total mesorectal excision (TME) was introduced as a surgical technique for resecting rectal cancer, with a goal of preserving autonomic nerve function and preventing urologic problems and sexual dysfunction. Thus, there are multiple subgroups of CRC survivors, depending upon tumor location, surgical technique, having an ostomy, and the use of preoperative radiotherapy. Further complicating the study of sexual function in CRC survivors is the fact that key outcomes and definitions of function differ between males and females and often differ from one study to another. Needless to say, the number of adequately powered prospective studies with a noncancer comparison population is low. Nevertheless, there are several key findings regarding sexual function that have been consistently reported across studies and should be addressed in evaluating a CRC survivor.

Even with contemporary surgical approaches intent on sparing autonomic nerve function, which is important for erectile function in males, the size and location of rectal cancer often precludes full preservation of nerve function. In addition, radiotherapy is a frequent method of local tumor control for rectal cancer (but not for colon cancer). Thus, in males, sexual dysfunction is more common among rectal cancer survivors than after radiotherapy for colon cancer. In a large population-based study of CRC survivors, 12 to 36 months after diagnosis, 25% of rectal cancer survivors reported difficulties with sexual matters, whereas 11% of colon cancer survivors reported difficulties. Den Oudsten and colleagues surveyed 1359 CRC survivors about 4 years after their initial diagnosis who were a mean age of 70 years at the time of the study. A higher proportion of male rectal cancer survivors reported erectile dysfunction (54%) than males in the normative (noncancer) population (27%). Similarly, male rectal cancer survivors frequently reported ejaculatory problems (68%). Despite these problems, there was no difference in sexual enjoyment between male rectal cancer survivors and men in the normative population. Moreover, male CRC survivors were fairly similar to the normative population with respect to erectile dysfunction, ejaculatory problems, and sexual enjoyment. In a well-designed prospective study of 990 patients who were diagnosed with rectal cancer at a mean age of 64 years and were randomized to TME with or without preoperative radiotherapy, Lange et al reported several interesting findings. Among men, 20.8% were not sexually active at the time of their cancer diagnosis. Of the men who were sexually active at time of cancer diagnosis, 28.5% were no longer active by 2 years after radiotherapy. Postoperative erectile dysfunction and ejaculatory problems developed or worsened in 79.8% and 72.2% of men, respectively. Unfortunately, there was not a noncancer comparison population in that study, so it is difficult to know how much normal aging influenced these changes. In multivariate models, anastomotic leakage and excessive perioperative blood loss (perhaps a proxy for surgical nerve damage) were associated with worsening function. Although radiotherapy was not independently associated with sexual dysfunction, the interval from radiotherapy to last evaluation was likely too short to determine the additive effect of radiation.

Female CRC survivors, regardless of whether the cancer was in the colon or the rectum, are substantially more likely to report sexual dysfunction, including dyspareunia, than women in the normative population. Whereas vaginal dryness appears to occur with similar frequency among colon and rectal cancer survivors, dyspareunia is more common in those treated for a rectal cancer. In the aforementioned prospective study by Lange and colleagues, only 51.7% of female CRC patients were sexually active at
the time of cancer diagnosis. Of those who were sexually active, 18.4% were no longer active by 2 years after the cancer diagnosis. Dyspareunia and vaginal dryness developed or worsened over time in 59.1% and 56.6% of women, respectively. A temporary or definitive stoma was the only factor in multivariate analysis that was associated with worsening of either outcome. Although radiotherapy was independently associated with general sexual dysfunction in women, it was not associated with the development of dyspareunia or vaginal dryness.

Multiple studies have shown a strong correlation between sexual dysfunction and psychosocial distress. Thus, primary care clinicians should address sexual function when managing CRC survivors. Some therapies are available for men and women who experience symptoms or signs of sexual dysfunction. In men, particularly those treated with pelvic radiotherapy, Leydig cell dysfunction should be evaluated and testosterone replacement initiated if indicated. The efficacy of oral phosphodiesterase-5 inhibitors for male rectal cancer survivors experiencing erectile dysfunction has been demonstrated in one RCT. Women with vaginal dryness may benefit from the use of vaginal moisturizers and water or silicone-based lubricants during intercourse, as recommended by the International Menopause Society for postmenopausal women without a cancer history. If available, referral for counseling and/or sexual health programs may be beneficial.

Urinary/Bladder Issues

**Recommendation 18:** (a) Screen CRC survivors for urinary incontinence and retention and (b) manage as you would a patient at average risk of urinary dysfunction. *Level of evidence = IC*

Urinary complications are common after treatment for CRC. Both surgery and radiation can affect the bladder and cause symptoms such as urinary incontinence or retention that affect QoL scores. Interestingly, the type of surgery (open vs laparoscopic) does not seem to make a difference in the Global Rating QoL scores. However, long-term urinary complications were more frequent in patients who underwent ostomies versus anastomosis, including urinary retention (ostomy, 6%; anastomosis, 1.3%) and urinary incontinence (ostomy, 2.1%; anastomosis, 0.0%). Functional voiding disturbances, such as stress, urge, or overflow incontinence, have all been reported postoperatively and may be deemed long-term effects. Urinary retention occurs when there is injury to the pelvic nerves during mobilization of the rectum. Newer surgical techniques have made this much less common; and, fortunately, this is often transient and does not progress as a long-term effect when recognized and treated early in the postoperative period. For patients with prolonged urinary retention after the surgery, referral to an urologist for urodynamic studies should be done to elucidate the diagnosis. Patients with hypococontractile bladders may require clean intermittent catheterization, whereas patients with adherence abnormalities may respond well to medical therapy with anticholinergic medications.

Stress and urge urinary incontinence are more common, with prevalence exceeding 50% up to 5 years postoperatively. However, this is difficult to interpret, as background rates of incontinence in the general population are also high. Evidence-based treatment guidelines are lacking for postsurgical incontinence in CRC survivors; thus, recommendations are based on interventions used in the general population. Kegel exercises can be helpful for stress incontinence due to pelvic floor dysfunction, but pelvic floor strengthening may be limited if denervation occurred during surgery. Other conservative therapies, such as dietary modification (limiting caffeine and fluid intake) or medications, may also be useful. Anticholinergic drugs are effective in stress incontinence, and antimuscarinic drugs are used for urge or mixed incontinence.

Pelvic radiation used as adjunctive therapy for CRC can lead to fibrosis of the bladder wall, weakening of the pelvic floor muscles, and thinning of the lining of the bladder. Urinary incontinence, frequency, urgency, dysuria, and hematuria are manifestations of radiation therapy for CRC that may persist after treatment ends in a small number of patients. There is no good evidence on which to base treatment guidelines; therefore, management is based on expert opinion and is aimed at controlling symptoms. For urgency and frequency, avoiding foods that irritate the bladder (citrus/tomatoes/caffeine) may be beneficial. Kegel exercises or bladder retraining are useful for incontinence. Persistent hematuria after radiation is rare; thus, a urology referral for cystoscopy may be warranted to look for other causes of hematuria.

**Health Promotion**

**Recommendation 19:** (a) Provide routine general medical care and health promotion recommendations, and (b) continue to treat patients’ chronic conditions, recognizing that cancer treatments worsen the severity of many underlying chronic conditions. *Level of evidence = 0, III (weight); 0, IB (physical activity); 0 (nutrition); 0, III (tobacco cessation); 0 (alcohol use)*

Health promotion recommendations for CRC survivors are provided in Table 5 (Table 5: Health Promotion Guidelines). Where appropriate, these guidelines leverage the ACS Nutrition and Physical Activity Guidelines for Cancer Survivors.

**Information**

CRC and caregiver information needs should be routinely assessed, and information about the late effects of CRC...
treatment, as well as information on risk reduction and health promotion, should be provided.

There are no completed, large, randomized trials directly assessing the impact of obesity, physical activity, specific dietary patterns, or tobacco use on CRC progression or mortality. However, there is a growing body of prospective and observational data supporting associations between these factors and outcomes in CRC survivors.

**Obesity**

Obesity is at epidemic proportions in the US and obesity rates of 17% to 35% have been reported in trials of adjuvant chemotherapy in patients with colon cancer. Increasing evidence indicates that being overweight or obese increases the risk of CRC recurrence and of being diagnosed with other obesity-related cancers. Several of these studies also suggest that obesity reduces the likelihood of disease-free and overall survival. CRC survivors should consume a well-balanced diet, and weight management should be considered a priority standard of care. Individuals who have recently faced a cancer diagnosis are often motivated to live a healthier lifestyle, particularly if the changes are linked to a higher likelihood of avoiding a recurrence. For CRC survivors who are overweight or obese, primary care clinicians should encourage increased physical activity and healthier eating, focusing on lower total calorie intake. Referral to weight-loss programs and frequent follow-up by the primary care clinician are appropriate interventions.

**Physical Activity**

Evidence suggests that increased physical activity levels are associated with better physical functioning, reduced fatigue, increased oxygen consumption, and better patient-reported QoL. A small number of studies also suggest that CRC survivors who increase their physical activity from prediagnosis to postdiagnosis may decrease their total mortality risk. CRC survivors may experience substantial benefits from increasing exercise, affecting multiple domains of well-being. Many cancer survivors may not feel ready to engage in the recommended exercise level of 150 minutes per week. Thus, attention should be given to helping patients gradually increase their activity levels with the goal of exercising 150 minutes per week.
**Nutrition**

Several dietary patterns including, higher intake of red and processed meat, refined grains, and sugary desserts, have been associated with a statistically significant increase in CRC recurrence and poorer overall survival.\(^{146,147}\) CRC survivors should follow nutritional guidelines to reduce their risk of a second primary cancer and of other chronic conditions, such as CVD. Following a diet that is high in vegetables, fruits, and whole grains is ideal, and diets should have low amounts of saturated fats as well as appropriate dietary fiber.

Additional diet and nutritional recommendations for CRC survivors based on these ACS guidelines include CRC survivors with chronic bowel problems or those who undergo surgery that affects normal nutrient absorption; these individuals should be referred to a registered dietitian to modify their diets to accommodate the changes and maintain optimal health (as described in the Bowel/Gastrointestinal Issues section) and to ensure that they have a sufficient vitamin D status and consume recommended levels of calcium.\(^{148,149}\)

**Smoking Cessation**

Studies have indicated that smokers who smoked before a diagnosis of CRC as well as those who smoke after diagnosis are nearly twice as likely to die as a result of their cancer and have more than double the risk of overall mortality compared with nonsmokers.\(^{150,151}\) Despite these risks, a recent survey found that nearly 10% of cancer survivors continued to smoke more than 9 years after their diagnosis.\(^{152}\)

Tobacco cessation is an important part of posttreatment care of cancer survivors. Primary care clinicians should counsel CRC survivors to avoid tobacco and offer cessation when appropriate.

In summary, it is recommended that primary care clinicians follow ACS Guidelines on Nutrition and Physical Activity for Prevention and Early Detection of Cancer and Nutrition and Physical Activity for Cancer Survivors to inform counseling on routine health promotion.

**Care Coordination and Practice Implications**

**Recommendation 20:** (a) Initiate and maintain direct communication with all specialists involved in your patient’s oncology care and symptom management; (b) request a treatment summary and follow-up care plan to guide coordination of follow-up care posttreatment. Level of evidence: 0, III (treatment summary and survivorship care plan); 0, I (care coordination for chronic conditions); 0 (psychosocial referral); 0 (rehabilitation referral); 0, I (follow-up care regimen)

The clinical follow-up care planning process and coordination among care providers are essential to ensure all health needs of the cancer survivor are met (Table 6: Care Coordination Guidelines). It is recommended that the primary care clinician initiate and maintain direct communication among oncology and specialty providers regarding clinical follow-up care. This communication should clearly specify the roles of clinicians related to clinical follow-up care. Patients completing primary treatment should be provided with a comprehensive treatment summary and clinical follow-up care plan (survivorship care plan [SCP]) from the primary treating specialist(s) who coordinated their oncology treatment. While the use of these tools has been endorsed, there are few high-quality studies of SCPs. Some have reported that survivor satisfaction with, and self-reported understanding of, their SCP were very high. One study found that breast cancer survivors with SCPs were better able to correctly identify the clinician responsible for their follow-up care, and another suggested a reduction of unmet needs among patients with SCPs. Health professionals have cited the time required to develop SCPs (1-4 hours) as a significant barrier to their implementation and use.\(^{153,154}\)

One of the central challenges confronting all health care clinicians dedicated to improving care for cancer survivors is the widespread lack of well-defined, smoothly functioning, interdisciplinary care teams. Many primary care clinicians have not focused specifically on what it means to serve as the leader or coordinator of a cancer survivor’s clinical team. Others believe they do not have the expertise to serve in this role. The need for this type of coordination has been widely accepted and is supported by available evidence, although that evidence base is immature. Primary care clinicians must now realize that it is the standard of care for all cancer patients to have a treatment summary and a SCP. Accordingly, primary care clinicians should initiate and maintain direct communication among the patient, specialty providers, and primary care clinicians regarding clinical follow-up care; clearly specify roles of clinicians related to clinical follow-up care; and proactively contact the oncology specialist to obtain a treatment summary and clinical follow-up care plan. The emergence of new payment models, such as accountable care organizations, may facilitate the development of this new higher level of coordination.

**Limitations**

A significant limitation of this review is the limited evidence base to provide clear and specific recommendations for the prevention and management of long-term and late effects. Lack of clinical trials is a limitation of the current state-of-the-science for survivorship and is also a limitation of the recommendations for management indicated in the tables. There are few prospective RCT’s testing interventions among CRC survivors. The majority of the citations characterizing the risk and magnitude of risk of late effects and management recommendations rely predominantly on case-
control studies with fewer than 500 participants and reviews that combine studies with various outcome measures. There were several cohort studies that used population-based data to estimate the risk of late effects.

Other limitations include lack of patient/consumer participation in the guideline process, lack of a radiation oncologist on the expert workgroup, and reliance on previous guidelines for surveillance. In addition, the literature review was not managed by a clinical epidemiologist due to limited resources. The literature review and environmental scan were conducted by project staff. An ACS librarian and the ACS Principal Investigator for The Survivorship Center were consulted for supplemental literature searches. Furthermore, the guidelines did not result directly from the development of specific clinical questions asked before the literature review, and recommendations for inclusion were not systematically evaluated through an instrument such as the Rigor of Development subscale of the Appraisal for Guidelines for Research and Evaluation (AGREE II).

Management recommendations are based on current evidence in the literature, but most evidence is not sufficient to warrant a strong recommendation. Rather, recommendations should be seen as possible management strategies given the current limited evidence base.

Summary

Considering the potential significant impacts of cancer and its treatment on CRC survivor health and QoL, it is imperative that cancer survivors receive high-quality, comprehensive, coordinated clinical follow-up care. This care should focus on both the physical and psychosocial impacts and take into consideration the individual’s treatment and needs. Historically, the focus of clinical follow-up care has been on surveillance for recurrence and screening for new cancers, but it is now clear that it should also entail detection and management of the long-term and late impacts. Moreover, cancer survivors need to be counseled on health promotion strategies to help minimize or mitigate these impacts. One key recommendation made here and elsewhere is that survivors and primary care clinicians should receive a SCP which includes a concise summary of treatment as well as a clinical follow-up care plan. This tool facilitates a discussion with the patient and all clinicians and presents an opportunity to improve care coordination by clarifying roles.

Despite gaps in the evidence base regarding critical components of clinical follow-up care, enough evidence exists to provide consensus-based guidelines to improve post-treatment care until additional evidence can be generated. This guideline on clinical follow-up care for CRC survivors is geared toward the diverse group of primary care clinicians who provide much-needed care for a wide variety of patients, some of whom may be CRC survivors.

In addition to this article, tools and resources are available to assist primary care clinicians in implementing the recommendations. This journal offers a Patient Page, which is a tool to help patients understand how to use the guidelines to talk to their doctor about surveillance and screening, symptom management, healthy behaviors, and care coordination. Primary care clinicians can access the free CA Patient Page for CRC survivors or download it from the journal website (onlinelibrary.wiley.com/doi/10.3322/caac.21294/pdf). The Survivorship Center offers The George
American Cancer Society 2012-2015 Colorectal Cancer Survivorship Care Guidelines Expert Workgroup

Volunteer Members: April L. Barbour, MD, MPH, FACP (Associate Professor of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC); Jennifer K. Bretsch, MS, CPHQ (Director, Performance Improvement, American Society of Clinical Oncology, Alexandria, VA); Corry Chapman, MD (Family Medicine Physician, Catholic Charities, Washington, DC); Zana Correa, NP, BC (Nurse Practitioner, Colorectal Survivorship Clinic, Memorial Sloan Kettering Cancer Center, New York, NY); Khaled El-Shami, MD, PhD (Assistant Professor of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC); Sarah Huff, RS, BSN, OCN (Colorectal Cancer Patient Navigator, David Lee Cancer Center, Charleston Area Medical Center, Charleston, WV); Paul J. Limburg, MD, MPH (Gastroenterology and Hepatology, Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Rochester, MN); Jeffrey A. Meyerhardt, MD, MPH (Clinical Director, Gastrointestinal Cancer Center, Senior Physician, Dana-Farber Cancer Institute; Associate Professor, Department of Medicine, Harvard Medical School, Boston, MA); Kevin C. Oeffinger, MD (Director, Cancer Survivorship Center, Memorial Sloan Kettering Cancer Center, New York, NY); Johnnie Rose, MD, PhD (Assistant Professor, Department of Family Medicine and Community Health, Case Western Reserve University School of Medicine/Case Comprehensive Cancer Center, Cleveland, OH); Sandra L. Wong, MD, MS, (Associate Professor of Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI); and Fran Zandstra, RN, MBA, OCN (Former Executive Director, Office of Cancer Survivorship (retired), The University of Texas MD Anderson Cancer Center, Houston, TX). The George Washington University Cancer Institute staff members: Mandi L. Pratt-Chapman, MA (Director, Washington, DC) and Anne Willis, MA (Director, Patient-Centered Programs, Washington, DC). American Cancer Society staff members: Durado D. Brooks, MD, MPH (Director, Cancer Control Intervention, Atlanta, GA); Rachel S. Cannady, BS (Behavioral Scientist, Behavioral Research Center/National Cancer Survivorship Resource Center, Atlanta, GA); Rebecca L. Cowens-Alvarado, MPH (Vice President, South Atlantic Health Systems, Atlanta, GA); Nicole L. Erb, BA (Program Manager, National Cancer Survivorship Resource Center, Atlanta, GA); Katherine B. Sharpe, MTS (Senior Vice President, Patient and Caregiver Support, Atlanta, GA); Robert A. Smith, PhD (Vice President, Cancer Screening, Atlanta, GA); and Kevin D. Stein, PhD (Vice President, Behavioral Research, Director, Behavioral Research Center, Atlanta, GA).

References

1. Institute of Medicine. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: The National Academies Press; 2005. Accessed April 29, 2015.

2. Reugen SH; for The President’s Cancer Panel. Living Beyond Cancer: Finding a New Balance. President’s Cancer Panel 2003-2004 Annual Report. Bethesda, MD: National Cancer Institute, National Institutes of Health, US Department of Health and Human Services; 2004. deinfo.nci.nih.gov/advisory/pcp/annualReports/pcp 03-04rpt/Survivorship.pdf. Accessed April 29, 2015.

3. Centers for Disease Control and Prevention. A National Action Plan for Cancer Survivorship: Advancing Public Health Strategies. Atlanta, GA: Centers for Disease Control and Prevention, Lance Armstrong Foundation; 2004.

4. Institute of Medicine. Medicine Care for the Whole Patient: Meeting Psychosocial Health Needs. Washington, DC: The National Academies Press; 2007.

5. Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 1985;313:270-273.

6. McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31: 631-640.

7. Benson AB, et al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer Version 2.2015. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed April 29, 2015.

8. Benson AB, et al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Rectal Cancer Version 2.2015. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed April 29, 2015.

9. Denlinger CS, et al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Survivorship—Version 2.2015. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed April 29, 2015.

10. Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 10 32:1840-1850, 2014.

11. Andersen BL, DeRubisi R, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol. 2014;32:1605-1619.

12. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32: 1941-1967.

13. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500-2510.

14. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of
palliative care into standard oncology care. J Clin Oncol. 2012;30:880-887.

15. Cowens-Alvarado R, Sharpe K, Pratt-Chapman M, et al. Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers. CA Cancer J Clin. 2013;63:147-150.

16. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:2-29.

17. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review 1975–2012. Bethesda, MD: National Cancer Institute; based on November 2014 SEER data submission, posted to the SEER website April 2015. seer.cancer.gov/csr/1975_2012/browse_csr.php#sectionSEL=1&pageSEL=sec_01_table.23.html.

18. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104-117.

19. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252-271.

20. Miller K, ed. Excellent Care for Cancer Survivors: A Guide to Fully Meet Their Needs in Medical Offices and in the Community. Santa Barbara, CA: Praeger; 2011.

21. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306:2495-2499.

22. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.

23. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31:4465-4470.

24. Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306:2495-2499.

25. Rosen J, Augestad KM, Cooper GS. Colorectal cancer surveillance: what’s new and what’s next. World J Gastroenterol. 2014;20:1887-1897.

26. Sarlomo-Rikala M, Sutinen I, Aunola S, et al. Long-term results of rectal cancer surgery and management of noncentral nervous system complications. Eur J Surg Oncol. 2005;31:735-742.

27. Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30-54.

28. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2005. CA Cancer J Clin. 2005;53:141-169.

29. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.

30. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009;10:400-408.

31. Barrow E, Robinson L, Alduailij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141-149.

32. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765-1772.

33. Breijer MC, Peeters JA, Opmeer BC, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261-269.

34. Lindor NM, Petersen GM, Hadley DW, et al. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97:1228-1234.

35. Emmertsen KJ, Laurberg S. Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2010;100:1377-1387.

36. Ramsey SD, Berry K, Moinpour C, et al. Long-term quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol. 2005;31:735-742.

37. Braendenberg M, Tvedt KM, Brueheim K, Cvanacarova M, Berglund A, Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonsmoking colorectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys. 2011;81:1017-1024.

38. Lange MM, Martz JE, Ramseb B, et al. Long-term results of rectal cancer surgery with a systematical operative approach. Ann Surg Oncol. 2013;20:1806-1815.

39. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch Colorectal Cancer Group study. J Clin Oncol. 2005;23:6199-6206.

40. Gami B, Harrington K, Blake P, et al. How patients manage gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther. 2003;18:987-994.

41. Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer. 2011;105(suppl 1):S29-S37.

42. Jensen SA, Sorensen JB. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol. 2012;69:57-64.

43. Polk V, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity [serial online]. BMC Pharmacol Toxicol. 2014;15:47.

44. Polk V, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974-984.

45. Martinez ME, Giovannucci E, Spiegelman D, Hunter DJ, Willett WC, Colditz GA. Long-term physical activity, body size, and colon cancer in women. Nurses’ Health Study Research Group. J Natl Cancer Inst. 1997;89:948-955.

46. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon and adenoma in men. Ann Intern Med. 1995;122:327-334.

47. Hawkes AL, Lynch BM, Owen N, Atkin JF. Lifestyle factors associated concurrently and prospectively with comorbidity cardiovascular disease in a population-based cohort of colorectal cancer survivors. Eur J Cancer. 2011;47:267-276.

48. Cramer H, Lauche R, Klose P, Dobos G, Langhorst J. A systematic review and meta-analysis of exercise interventions for colorectal cancer patients. Eur J Cancer Care (Engl). 2014;23:3-14.

49. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435-1441.

50. Wefel JS, Kesler SR, Noll KR, Schagen SB. Characteristic, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65:123-138.

51. Jean-Pierre P, Winters PC, Ahles TA, et al. Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Clin Oncol. 2012;30:30-34.

52. Jansen L, Hoffmeister M, Chang-Claude J, Koch M, Brenner H, Arndt V. Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: a population-based prospective cohort. Oncologist. 2011;16:1741-1751.

53. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22:2233-2239.

54. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7:300-322.

55. Boyes AW, Girgis A, Zueca AC, Lecathelinais C. Anxiety and depression
among long-term survivors of cancer in Australia: results of a population-based survey [comment]. Med J Aust. 2009;191: 295.
58. Hoffman KE, McCarthy EP, Reckittis CJ, Ng AK. Psychological distress in long-term survivors of colorectal cancer: results from a national survey. Arch Int Med. 2009;169:1274-1281.
59. Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14:721-732.
60. Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. J Natl Compr Canc Netw. 2009;7:883-893; quiz 894.
61. Ross L, Ablid-Nielsen AG, Thomsen BL, Oshima CT, Forones NM. Medeiros M, Oshima CT, Forones NM. Ross L, Abild-Nielsen AG, Thomsen BL, Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14:721-732.
62. Holland JC, et al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)® Distress Management Version 1.2015. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed June 16, 2015.
63. Patel D, Sharpe L, Thewes B, Bell ML, Clarke S. Using the Distress Thermometer and Hospital Anxiety and Depression Scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. J Affect Disord. 2011;131(1-3):412-416.
64. Campbell HS, Sanson-Fisher R, Turner D, Hayward L, Wang XS, Taylor-Brown J. Psychometric properties of cancer survivors’ unmet needs survey. Support Care Cancer. 2010;19:221-230.
65. Campbell HS, Hall AE, Sanson-Fisher RW, Barker D, Turner D, Taylor-Brown J, Development and validation of the Short-Form Survivor Unmet Needs Survey (SF-SUNS). Support Care Cancer. 2014;22:1071-1079.
66. Mayo Clinic. Diseases and Conditions: Depression [major depressive disorder]. Diseases and Conditions. Rochester, MN: Mayo Foundation for Medical Education and Research; 2014. mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977. Accessed November 7, 2014.
67. Mayo Clinic. Diseases and Conditions: Anxiety. Rochester, MN: Mayo Foundation for Medical Education and Research; 2014. mayoclinic.org/diseases-conditions/anxiety/basics/definition/con-20026282. Accessed November 7, 2014.
68. Medeiros M, Oshima CT, Forones NM. Depression and anxiety in colorectal cancer patient. J Gastrointest Cancer. 2010;41:179-184.
69. Zignodin AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
70. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997;12:277-287.
71. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
72. Kreeber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patient: a meta-analysis of interviews and self-report instruments. Psychooncology. 2014;23:121-130.
73. Kuchler T, Bestmann B, Rappat S, Henne-Bruns D, Wood-Dauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 2007;25:2702-2708.
74. Sharma A, Walker LG, Monson JR. Baseline quality of life factors predict long term survival after elective resection for colorectal cancer. Int J Surg Oncol. 2013;269510-269510, 2013.
75. Mishra SI SR, Geige PM, et al. Exercise interventions on health-related quality of life for cancer survivors [serial online]. Cochrane Database Syst Rev. 2012;8: CD007566.
76. Berger AM, et al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)® Cancer-Related Fatigue Version 2.2015. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed April 29, 2015.
77. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120:425-432.
78. Yanez B, Pearman T, Lis CG, Beaumont JL, Cella D. The FACT-G: a rapid version of the Functional Assessment of Cancer Therapy-General (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol. 2013;24:1073-1078.
79. Wang XS, Cleeland CS, Mendoza TR, et al. Impact of psychosocial factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010;102:732-738.
80. Minton O, Strasser F, Radbruch L, Stone P. Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage. 2012;43:226-235.
81. Kuhnt S, Ernst J, Singer S, et al. Fatigue in cancer survivors—prevalence and correlates. Onkologie. 2009;32:312-317.
82. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
83. Servaes P, Gielissen MF, Verhagen S, Kiernan MC. Oxaliplatin-induced neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507-1515.
84. Cheryl CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
85. Janjan NA, Wang XS, Mendoza T, et al. Utility of the MD Anderson Symptom Assessment Inventory (MDASI) for symptom evaluation during chemotherapy in patients with gastrointestinal malignancies [abstract]. J Clin Oncol. 2007;25(18S). Abstract 6613.
86. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
87. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development, scale validation and interpretation of the Fatigue Symptom Inventory, Qual Life Res. 1998;7:301-310.
88. Stein KD, Martin SC, Hann DM, Jacobsen PB. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract. 1998;6:143-152.
89. Chambers SK, Meng X, Youl P, Atikcn J, et al. The FACT-G: a brief measure of fatigue for use with cancer patients. J Pain Symptom Manage. 2007;33:119.4.
90. Schoder-Andree AE, Courneya KS. Effects of exercise on quality of life and prognosis in cancer survivors. Curr Sports Med Rep. 2009;8:176-181.
91. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507-1515.
92. Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22:1999-2007.
93. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neuropathy and the development of neuropathy. Muscle Nerve. 2005;32:51-60.
101. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004;12:619-625.

102. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9-17.

104. Tavandoust S, Joshi R, Pittman KB, et al. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer. 2014;22:513-518.

112. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1539-1546.

118. Schmidt-Hansen M, Bennett MJ, Arnold S, Brouwers EE, Huitema AD, Boogerd W, etc. oxaliplatin.

124. Ho VP, Lee Y, Stein SL, Temple LK. Sexual dysfunction in colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2011;31:2699-2707.

130. Traa MJ, Orsini BG, Den Oudsten BL, et al. Measuring the health-related quality of life and sexual functioning of patients with rectal cancer: does type of treatment matter? Int J Cancer. 2014;134:979-987.

131. Ball M, Nelson CJ, Shuk E, et al. Men’s experience with diagnostic and rectal cancer treatment: a qualitative study. J Cancer Educ. 2013;28:494-502.

132. Carter J, Stabile C, Seidel B, et al. Baseline characteristics and concerns of female cancer patients/survivors seeking treatment at a Female Sexual Medicine Program [published online ahead of print January 8, 2013]. Support Care Cancer. 2015. doi: 10.1007/s00520.

133. Park SY, Choi GS, Park JS, Kim HJ, Park JA, Choi J. Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: a randomized, double-blind, placebo-controlled trial. Surgery. 2015;157:64-71.

134. Sturdie DW, Panay N; International Menopause Society Working Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13:509-522.

135. Averly JC, Nishimoto PW. Addressing sexual dysfunction in colorectal cancer survivors. J Gastrointest Oncol. 2014;5:388-394.

136. Korolija D, Sauerland S, Wood-Dauphinee S, et al. Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery. Surg Endosc. 2004;18:879-897.

137. Delacroix SE Jr, Winters JC. Voiding dysfunction after pelvic colorectal surgery. Clin Colon Rectal Surg. 2010;23:119-127.

138. Panjari M, Bell RJ, Burney S, Bell S, McMurtick PJ, Davis SR. Sexual function, incontinence, and wellbeing in women after rectal cancer—a review of the evidence. J Sex Med. 2012;9:2749-2758.

139. Lange MM, van de Velde CJ. Fecal and urinary incontinence after multimodality treatment of rectal cancer [serial online]. PLoS Med. 2008;5:e202.

140. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243-274.

141. Sinicrope FA, Foster NR, Yethers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013;119:1528-1536.

142. Gibson TM, Park Y, Robien K, et al. Body mass index and risk of second obesity-associated cancers after colorectal cancer: a pooled analysis of prospective cohort studies. J Clin Oncol. 2014;32:4004-4011.

143. Dignam JN, Polite BN, Yethers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647-1654.

144. Meyerhardt JA, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243-274.
145. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. *Ann Oncol.* 2014;25:1293-1311.

146. Meyerhardt JA, Sato K, Niedzwiecki D, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *J Natl Cancer Inst.* 2012; 104:1702-1711.

147. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA.* 2007; 298:754-764.

148. US Department of Health & Human Services, National Institutes of Health, Office of Dietary Supplements. Vitamin D. Fact Sheet for Health Professionals. Bethesda, MD: National Institutes of Health, Office of Dietary Supplements; 2014. ods.od.nih.gov/factsheets/list-all/VitaminD-HealthProfessional/. Accessed April 29, 2015.

149. US Department of Health & Human Services, National Institutes of Health, Office of Dietary Supplements. Calcium. Dietary suppl Fact Sheet. Bethesda, MD: National Institutes of Health, Office of Dietary Supplements; 2013. ods.od.nih.gov/factsheets/Calcium-HealthProfessional/. Accessed April 29, 2015.

150. Yang B, Jacobs EJ, Gapstur SM, Stevens V, Campbell PT. Active smoking and mortality among colorectal cancer survivors: the Cancer Prevention Study II nutrition cohort. *J Clin Oncol.* 2015;33:885-893.

151. Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. *Br J Cancer.* 2014;110:1359-1366.

152. Westmaas JL, Alcaraz KL, Berg CJ, Stein KD. Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis. *Cancer Epidemiol Biomarkers Prev.* 2014;23:1783-1792.

153. Mayer DK, Birken SA, Check DK, Chen RC. Summing it up: an integrative review of studies of cancer survivorship care plans (2006–2013). *Cancer.* 2015;121:978-996.

154. Brennan ME, Gormally JF, Butow P, Boyle FM, Spillane AJ. Survivorship care plans in cancer: a systematic review of care plan outcomes. *Br J Cancer.* 2014;111:1899-1908.